Overcoming Resistance to Immune Checkpoint Blockade in Liver Cancer with Combination Therapy: Stronger Together?

Abstract

Primary liver cancer, represented mainly by hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (CCA), is one of the most common and deadliest tumors worldwide. While surgical resection or liver transplantation are the best option in early disease stages, these tumors often present in advanced stages and systemic treatment is required to improve survival time. The emergence of immune checkpoint inhibitor (ICI) therapy has had a positive impact especially on the treatment of advanced cancers, thereby establishing immunotherapy as part of first-line treatment in HCC and CCA. Nevertheless, low response rates reflect on the usually cold or immunosuppressed tumor microenvironment of primary liver cancer. In this review, we aim to summarize mechanisms of resistance leading to tumor immune escape with a special focus on the composition of tumor microenvironment in both HCC and CCA, also reflecting on recent important developments in ICI combination therapy. Furthermore, we discuss how combination of ICIs with established primary liver cancer treatments (e.g. multikinase inhibitors and chemotherapy) as well as more complex combinations with state-of-the-art therapeutic concepts may reshape the tumor microenvironment, leading to higher response rates and long-lasting antitumor immunity for primary liver cancer patients.

 

MissingLinkText

Keywords

hepatocellular carcinoma - cholangiocarcinoma - immunotherapy - checkpoint inhibitors - resistance

Primary liver cancer, most frequently represented by hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (CCA), is the sixth most diagnosed cancer worldwide.[1] While it is very common in China and other East Asian countries,[2] frequency has increased in countries with formerly low incidence rates such as the United States and some European countries.[3] Its prognosis is often fatal, which is reflected in the almost equal ratio between newly diagnosed liver cancer patients and liver cancer–related deaths per year (1.09 in 2020).[2] This deadliness can be attributed to the fact that most patients are diagnosed in advanced disease stages when curability (through resection, local therapy, or liver transplantation) is no longer an option.[4] [5] In addition, systemic therapies—mainly multikinase inhibitors (MKIs) for HCC and the chemotherapy regimen gemcitabine plus cisplatin (Gem/Cis) for CCA[6] [7]—became available only in the late 2000s and are characterized by low response rates and only moderate survival benefits.[8] [9] [10] [11] [12] [13] Since then, new chemotherapeutic options have not been able to considerably extend the survival of liver cancer patients for a long time.

Since ipilimumab, an antibody against cytotoxic T lymphocyte antigen 4 (CTLA-4), became the first immunotherapy approved by the Food and Drug Administration (FDA)[14] and European Medicines Agency (EMA)[15] for late-stage melanoma in 2011, immune checkpoint inhibitor (ICI) therapy has revolutionized cancer therapy. Followed by approval of antibodies against programmed death 1 (PD-1), namely, pembrolizumab and nivolumab, in 2014, ICI therapy began its victory march, prolonging survival times for a plethora of hematologic and solid cancers.[16] [17] The first phase I/II trials for nivolumab[18] and pembrolizumab[19] in patients with HCC showed promising effects as well. However, only 15 to 20% of patients showed objective responses, and follow-up phase III trials for first- and second-line therapy with single ICI agents did not display survival benefits in comparison to sorafenib.[20] [21] Therefore, as ICI therapy is able to provide durable and long-term antitumor effects if patients respond, increasing response rates is a main objective for future ICI therapy of liver cancer.

In this review, we will summarize the evolution of ICI therapy in advanced liver cancer therapy—starting with the first monotherapy trials and tumor microenvironment (TME)-associated mechanisms of resistance. We will demonstrate why combination therapy is an effective way to bypass ICI resistance as well as describe current and future ICI combination therapy options to increase response rates and survival in patients with liver cancer.

Immune Checkpoint Inhibitors in Primary Liver Cancer

The Concept of Disturbed Immune Surveillance in the Cancer Immune Cycle

Paul Ehrlich suggested a potential tumor-controlling role of the immune system, which has been formally introduced as cancer immune surveillance in the 1950s.[22] At that time, this hypothesis was abandoned by the scientific community due to lack of evidence but revived in a hallmark review from 2002, which evolved this theory and described the development of neoplasms despite a functioning host immune system as cancer immunoediting.[23] During elimination phase or immune surveillance, the immune system is able to eradicate degenerated cells by careful orchestration of innate and adaptive immune responses, mainly mediated by CD8+ T lymphocytes or cytotoxic T cells (CTLs; [Fig. 1]).[23] Briefly, the (immunogenic) death of tumor cells releases tumor-associated antigens (TAA) and danger-associated molecular patterns (DAMP). Following antigen uptake and processing, activated antigen presenting cells (APC) migrate to the draining lymph nodes (or to tertiary lymphoid structures), where they cross-present the antigens and prime CTL. Activated CTL then travel back to the tumor and kill tumor cells by antigen-mediated cytotoxicity. Other lymphocyte subsets, such as natural killer (NK) cells[24] and CD4+ T cells,[25] can exert or support antitumor cytotoxicity as well. Each of these individual steps can be influenced and modified by precancerous alterations, making them rate-limiting for a successful antitumor response.[26] Due to selection pressure, less immunogenic cancer cells evolve and escape the immune system, further expanding with the help of additional immunosuppressive adaptations.[23]

Fig. 1 Reshaping the tumor microenvironment (TME) to reestablish immunosurveillance in primary liver cancer. During the cancer immunity cycle,[26] immunogenic cell death (ICD) and cells of innate immunity recruit professional antigen-presenting cells (APC) to the tumor (1). APC process and present tumor-associated antigens (TAA) during their maturation (2) and relocate to the tumor-draining lymph node (3), where they cross-present and prime naive cytotoxic T lymphocytes (CTL) (4). Following clonal expansion (5), TAA-experienced activated CTL migrate to the tumor and infiltrate the TME (6), where they recognize and kill tumor cells (7). Various mechanisms of tumor immune escape are implemented in the TME, which is represented in four different schematic manifestations (based on Galon and Bruni[50]). While the hot TME (lower left) shows high CTL infiltration, programmed death ligand 1 (PD-L1) expression and IFN-γ signaling, cold TME (upper left), display near to no CTL infiltration or PD-L1 expression. The excluded TME (upper right) is rich in cancer-associated fibroblasts and T cells in the periphery but not in the tumor center, and the immunosuppressive TME (lower right) shows heightened infiltration of immunosuppressive cells. TME frequencies in HCC and CCA are based on Job et al and Giraud et al.[214] [243] Established and experimental cancer therapies combined with immune checkpoint inhibitor therapy (blue boxes) may alter the TME and facilitate reentry into the cancer-immunity cycle. (Created with biorender.com.) CAF, cancer-associated fibroblasts; CCA, cholangiocarcinoma; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; CXCR, C-X-C-chemokine receptor; DAMP, danger-associated molecular patterns; Flt3L, FMS-like tyrosine kinase 3 ligand; IL, interleukin; FGFR, fibroblast growth factor receptor; HCC, hepatocellular carcinoma; LAG-3, lymphocyte-activation gene 3; MHC, major histocompatibility complex; MKI, multikinase inhibitor; PD-(L)1, programmed death (ligand) 1; TGF-β, tumor growth factor-beta; TIM-3, T cell immunoglobulin and mucin-domain-containing molecule 3; TLR, toll-like receptor; VEGF(R), vascular endothelial growth factor (receptor).

 

MissingLinkText

Commonly Applied Immune Checkpoint Inhibitors in Cancer Immunotherapy

Inhibitory immune checkpoints are important regulators of the immune system, hindering excessive immune responses by putting a break on T cell–mediated adaptive immune functions and facilitating self-tolerance.[27] However, T cell–mediated cytotoxicity against cancer cells can also be prevented by the same mechanisms.[28]

The best studied immune checkpoints to date are CTLA-4 and the PD-1/PD ligand 1 (PD-L1) axis.[29] [30] Activated T cells express CTLA-4 on their surface, where it competes with CD28 for B7 ligands CD80/86 on APC.[30] [31] While binding of CD28 has a costimulatory effect, ensuring activation and differentiation of T cells, CTLA-4 functions as an inhibitor with far higher affinity for CD80/CD86 than CD28.[32] [33] CTLA-4 has two modes of action in the cancer immunity cycle, which ultimately lead to immunosuppression: during T cell priming in the draining lymph node, antigen recognition of naive T cells is hindered by undermining the costimulatory signal mediated by CD80/CD86 and regulatory T cells (T_reg), which constitutively express CTLA-4, inhibit costimulatory signals on dendritic cells (DC) leading to anergy during antigen presentation and reduced T cell priming ([Fig. 1]). Additionally, CTLA-4-expressing T_reg hampers antigen-mediated T cell killing in the TME ([Fig. 1]). Blocking CTLA-4 with monoclonal antibodies revives the costimulatory signal necessary for T cell activation and induces elimination of T_reg by antibody-dependent cellular cytotoxicity.[30] [34] Ipilimumab was the first FDA-approved CTLA 4-inhibitor for solid cancers (i.e., melanoma).[14]

The PD-1 receptor is expressed on activated T and B cells, NK cells, and monocytes, and produces a negative signal cascade when binding to its ligands PD-L1/L2 on APC and tumor cells, inhibiting T and B cell receptor signaling, cytokine production, and production of proapoptotic proteins.[30] [35] Especially chronic antigen stimulation by uninterrupted carcinogenesis can cause upregulation of PD-1 and other checkpoints, consequently leading to loss of T cell effector functions (called T cell exhaustion) and further assisting cancer immune escape ([Fig. 1]).[36] Treatment with antibodies against PD-1 (e.g., nivolumab, pembrolizumab) or PD-L1 (e.g., atezolizumab, durvalumab) prevents binding of the natural ligands, inhibiting the immunosuppressive function of PD-1 and ensuring proper T cell function.[30] [37]

Additionally, alternative checkpoints like lymphocyte activation gene-3 (LAG-3) and T cell immunoglobulin and mucin domain-containing molecule 3 (TIM-3) have become increasingly interesting in the treatment of solid tumors.[38] LAG-3 and TIM-3 are transmembrane proteins expressed by activated T cells and have a similar function to PD-1 and CTLA-4. While LAG-3 exerts the inhibitory function either as a ligand for MHC class II or fibrinogen-like protein 1,[39] TIM-3 is also expressed by other immune cell types such as DC, T_reg, and NK cells, and activates inhibitory signaling through interactions with HLA-B-associated transcript 3 and galectin 9.[40] Clinical trials investigating the combination of both checkpoints are ongoing.[38] [41]

 

MissingLinkText

Monotherapy Trials for Primary Liver Cancer

The first ICI monotherapy phase I/II trial conducted in primary liver cancer (CheckMate 040), starting in 2012, tested dose escalation and expansion of the PD-1 inhibitor nivolumab involving 262 patients with advanced HCC after first-line treatment with sorafenib.[18] Nivolumab managed to achieve an objective response rate (ORR) of 20% in the final-dose expansion phase as well as a median overall survival (mOS) of 13.2 months with a manageable safety profile. Because of these positive results, a randomized, placebo-controlled phase III trial (CheckMate 459, [Table 1]) compared the effect of nivolumab monotherapy to sorafenib as first-line treatment.[20] The nivolumab treatment arm did not reach its primary endpoint, demonstrating no significant survival benefit compared to sorafenib. Still, nivolumab was discussed by the authors as an option for patients with contraindication(s) to sorafenib,[20] and the favorable safety profile already displayed in CheckMate 040 led to FDA approval of nivolumab as second-line option following sorafenib treatment.[42]

Table 1 Selected phase III ICI monotherapy trials in advanced or unresectable HCC

Trial	Time of recruitment	Treatment	Line of therapy	Participants	Etiology		Disease stage		Median OS (mo)	Median PFS (mo)	ORR (%)	DCR (%)	Ref.
				n	Viral (%)	Nonviral (%)	EHD (%)	BCLC C (%)
CheckMate 459	01/2016–05/2017	Nivolumab	1st-line HCC	371	54	45	60	82	16.4	3.8	15	55	[20]
		Sorafenib		372	54	45	56	78	14.7	3.9	7	58
KEYNOTE-240	05/2016–11/2017	Pembrolizumab + BSC	2nd-line HCC	278	41.4	58.6	70.1	79.9	13.9a	3.0b	18.3c	62.2a	[21]
		Placebo + BSC		135	37.1	63	68.9	78.5	10.6	2.8	4.4	53.3
KEYNOTE-394	05/2017–12/2019	Pembrolizumab + BSC	2nd-line HCC	300	80.4	19.6	77.3	92.3	14.6a	2.6b	12.7c	51	[45]
		Placebo + BSC		153	81.7	18.3	78.4	95.4	13.0	2.3	1.3	47.1
RATIONALE-301	12/2017–10/2019	Tislelizumab	1st-line HCC	342	76.1	24	64	79.5	15.9a	2.1	2.1	44.2	[173]
		Sorafenib		332	75.8	24.1	59.6	75.9	14.1	3.4	3.4	50.3

Abbreviations: BCLC, Barcelona Clinic Liver Cancer criteria; BSC, best supportive care; DCR, disease-control rate; EHD, extrahepatic disease; HCC, hepatocellular carcinoma; ICI, immune checkpoint inhibitor; NR, not reached; ORR, objective response rate; OS, overall survival; PFS, progression-free survival, STRIDE, single tremelimumab regular interval durvalumab; TKI, tyrosine kinase inhibitor.

Statistics: one-sided ^a< 0.05, ^b p < 0.01, ^c p < 0.0001.

Another PD-1 inhibitor, pembrolizumab, was investigated in the phase II KEYNOTE-224 trial.[19] In line with CheckMate 040, the patients were previously treated with sorafenib, and either developed intolerance or showed disease progression. The ORR was 17% (1% complete response, 16% partial responses), the mOS was 12.9 months, and progression-free survival (PFS) was 4.9 months. A follow-up analysis in 2022 even updated the ORR to 18.3% and the mOS to 13.2 months.[43] Following these encouraging results, the randomized, double-blinded phase III trial KEYNOTE-240 ([Table 1]) tested pembrolizumab as second-line treatment and included 413 patients with advanced HCC who were previously treated with sorafenib in comparison to placebo.[21] Although the trial did not reach statistical significance in 2019, the follow-up in 2020 showed an ORR of 18.3%, a mOS of 13.9 months, and a PFS of 3 months for pembrolizumab (placebo: ORR: 4.4%, mOS: 10.6 months, PFS: 2.8 months).[44] Similar results were shown by KEYNOTE-394 ([Table 1]), which focused on a primarily Asian cohort.[45] The results were in line with KEYNOTE-240, showing comparable clinical activity and risk profile to other pembrolizumab studies.[19] [21] [43] [44]

There have been no large phase III trials investigating ICI monotherapy specifically in CCA. However, the uncontrolled phase II trial KEYNOTE-158 reported a clinical benefit for pembrolizumab monotherapy in pretreated solid tumors with high levels of microsatellite instability.[46] [47]

In conclusion, ICI monotherapy trials showed an ORR between 12.7 and 18.3% in HCC patients, which is better than standard systemic therapies like sorafenib[6] in first-line and regorafenib[9] in second-line. However, at this point, the ORR and overall survival benefit remain moderate and comparable to the standard therapies.

 

MissingLinkText

 

MissingLinkText

Mechanisms of Primary Resistance

One of the main reasons for the moderate efficacy of ICI monotherapy in liver cancer is the relatively high rate of primary therapy resistance—meaning the tumor does not respond to therapy right from the beginning.[48] Primary resistance to immunotherapy strongly depends on cancer type–specific and patient–individual factors, with the composition of the TME playing a major role in shaping therapy response.[49] [50] [51] [52] In brief, an inflamed (or hot) TME shows high infiltration of CTL inside the tumor and the surrounding stroma, alongside high tumor mutational burden (TMB), heightened PD-L1 and interferon (IFN)-γ expression, and has been associated with favorable ICI therapy response.[53] In contrast, a cold TME is deserted of any T cell infiltration or PD-L1 expression, and excluded TME display CTL and other effector cells gathering on the tumor margin without being able to infiltrate due to stromal barriers and deviant vascular structure.[54] Finally, immunosuppressed TME shows moderate T cell infiltration and counteracting immunosuppressive adaptation of the TME such as high expression of interleukin (IL)-10 and transforming growth factor-beta (TGF-β), as well as excessive amounts of T_reg, tumor-associated macrophages (TAM), and myeloid-derived suppressor cells (MDSC; [Fig. 1]).

In general, primary resistance mechanisms are categorized into intrinsic and extrinsic mechanisms[55] [56]— we will describe these in the following sections, mainly focusing on the TME, as primary resistance in HCC has recently been discussed in detail in Seminars in Liver Disease.[57]

Tumor Intrinsic Mechanisms

Since successful immune responses to liver cancer depend heavily on correct priming and activation of T cells by APC, tumor intrinsic reasons for primary resistance mainly involve dysfunctional antigen expression or recognition, often caused by a lack of neoantigens, impaired antigen presentation, and mutations of resistance-associated genes and signaling pathways ([Fig. 2]).

Fig. 2 Intrinsic and extrinsic mechanisms of primary resistance. Tumor intrinsic mechanisms are caused by mutations of genes driving resistance-associated signaling pathways (1) that impair function and efficacy of the immune response by enhancing immunosuppressive properties of regulatory T cells (T_reg) (2) through stimulated release of immunosuppressive cytokines (3). Reduced availability of tumor-associated antigens (TAA) (4) causes disrupted antigen presentation resulting in impaired activation of cytotoxic T lymphocytes (CTL) (5). Tumor extrinsic mechanisms involve overexpression of programmed cell death ligand 1 (PD-L1) and alternative checkpoints (6) that reduce cytotoxicity of CTL (7), and recruitment of immunosuppressive cells such as cancer-associated fibroblasts (CAF), myeloid-derived suppressor cells (MDSC), tumor-associated macrophages (TAM), and T_reg that prevent tumor infiltration by T cells and NK cells (8). TAM can also promote tumor proliferation (9) and angiogenesis. (Created with biorender.com.) CAF, cancer-associated fibroblasts; CCL, C -C-chemokine; DC, dendritic cell; IFN, interferon; IL, interleukin; MDSC, myeloid-derived suppressor cells; NK, natural killer; PD-(L)1, programmed death (ligand) 1; PTEN, phosphatase and tensin homolog; TAM, tumor-associated macrophage; TGF-β, tumor growth factor-beta; TIM-3, T cell immunoglobulin and mucin domain-containing molecule 3; T_reg, regulatory T cell; VEGF, vascular endothelial growth factor.

Neoantigens are TAA that are expressed due to cancer-related mutations and play an important role in T cell activation.[58] A low TMB results in a lower quantity of neoantigens in the TME and therefore a lack of tumor immunogenicity,[59] suggesting that TMB might be a suitable biomarker for predictions of ICI therapy efficacy.[60] [61] As such, the TMB showed promise as a predictive biomarker for patients with lung, bladder, and head and neck cancers,[62] but its significance heavily depends on the type of solid tumor, the intratumoral CTL levels, and the abundance of neoantigens, resulting in failure to predict an ICI response in cancers like glioma, prostate cancer, and breast cancer.[63] While the TMB can vary depending on the stage, progression, and subtype of primary cancer, it is known to be relatively low in both HCC and CCA[64] [65] and a small case series of HCC patients found no correlation between TMB and ICI response.[66] Interestingly, CCA patients with microsatellite-instability high showed a higher TMB and longer survival after ICI treatment, suggesting that while the TMB should not be used as a sole predictive biomarker its impact should be considered for treatment.[67] In addition, CCA tumors are known to have a predominantly cold phenotype and show downregulation of genes responsible for antigen presentation,[68] which greatly impairs the priming function of APC.[69] Excess lipid accumulation and a subsequent overload of DC in HCC are additional reasons for dysfunctional antigen presentation in liver cancer.[70] [71]

Mutations of genes in important signal transduction pathways—such as the Wnt/β-catenin pathway, which is altered by mutations in many human cancers[72] and especially prevalent in HCC[73]—can also impact the TME and increase the probability of immune evasion of the tumor contributing to primary resistance.[74] Upregulated β-catenin increases PD-L1 expression with a subsequent reduction of cytotoxicity of CTL, inhibition of DC and T cell recruitment, and enhanced immunosuppression by T_reg.[75] In HCC, β-catenin drives transcription of telomerase reverse transcriptase (TERT), which encodes the catalytic subunit of telomerase and is partly responsible for increased tumorigenesis and resistance.[76] Additionally, the canonical Wnt/β-catenin pathway can be stimulated by TGF-β,[77] a mediator that enhances fibrogenesis in the liver and is abundant in an immunosuppressive TME,[78] further promoting tumor proliferation and causing a TME deprived of APC and CTL.[79] In mouse models, β-catenin activation has been shown to promote immune evasion and resistance to anti-PD-1 monotherapy of HCC,[80] which could be overcome by combination therapy (anti-PD-L1 and anti-VEGF).[81] However, data from human trials are conflicting. While several studies found no correlation between these mutations and therapy efficacy, both for atezolizumab and bevacizumab combination therapy[82] and anti-PD-1 monotherapy,[83] the Imbrave150 trial reported a greater survival benefit for patients without mutations of the Wnt/β-catenin pathway treated with atezolizumab/bevacizumab.[81] Further research is needed to explore the dual nature of Wnt/β-catenin mutations, which appear not to be indicative of a universally negative prognosis but rather dependent on the type of applied ICI therapy.

Another driving factor may be mutations of the TP53 gene encoding the p53 transcription factor, a sensor for cellular stress also known as “guardian of the genome”, which are common occurrences in cancer patients. In HCC, TP53 mutations correlate with a noninflamed TME and reduced survival of patients.[84] It has been shown that certain TP53 mutations can induce the Wnt/β-catenin pathway,[85] although the exact interplay of these pathways is still being studied. Additionally, infiltration of T cells in multiple tumors and therefore ICI efficacy can be negatively impacted by loss of phosphatase and tensin homolog (PTEN) and a subsequent activation of the PI3K/AKT pathway.[86] This pathway is dysregulated both in CCA and HCC.[87] [88] Other notable mutations in HCC and CCA are of the MYC oncogene and Kirsten rat sarcoma virus (KRAS) gene, which in turn induces overexpression of the MYC oncogene, leading to increased oncogenesis, suppressed immunity and antigen presentation, and activated TGF-β signaling.[89] [90] [91] [92] [93] Likewise, isocitrate dehydrogenase 1 (IDH1) mutations are common in CCA[94] and have been linked to immune evasion in mouse models.[95] Finally, signaling pathways like mammalian target of rapamycin (mTOR),[96] TGF-β,⁷⁸ and IFN-γ/JAK/STAT[97] [98] are frequently affected by mutations in primary liver cancer, promoting tumor proliferation and potentially adding to ICI resistance.

 

MissingLinkText

Tumor Extrinsic Mechanisms

Contrary to tumor intrinsic mechanisms, extrinsic mechanisms promote resistance to ICI therapy through cells, cytokines, and metabolites not originating from the tumor. This includes T cell–related events like alternative checkpoint inhibition, T cell exhaustion, recruitment of immunosuppressive cells like T_reg, TAM, MDSC, or cancer-associated fibroblasts (CAF), and the effect of immunosuppressive cytokines and chemokines released from tumor cells and immune cells ([Fig. 2]).

T_reg physiologically maintains self-tolerance and immune homeostasis, which is crucial in the liver but creates an avenue for tumors to evade host immunity. Multiple mechanisms exist for T_reg to suppress immune responses,[99] for example, through the disruption of DC function or release of immunosuppressive cytokines like IL-10, IL-35, or TGF-β, which downregulate effector T cell functions.[48] TME-resident T_reg, as well as TAM, CAF, and MDSC, can prevent tumor infiltration by CTL and NK cells in HCC and CCA[100] [101] and high T_reg to effector cell ratios are associated with worse clinical outcomes in ICI-treated HCC.[81] Studies have also shown that high TGF-β expression predicts poor prognosis in HCC and CCA,[102] [103] [104] thus potentially promoting primary resistance to ICI therapy.

MDSC are immunosuppressive cells that stem from immature myeloid cells whose differentiation into granulocytes, macrophages, or DC is prevented by the TME. MDSC are present only in patients with pathological conditions like cancer, and they promote angiogenesis and metastasis of tumors while showing immunosuppressive effects upon activation.[105] They can interrupt the cell cycle of T cells and trigger cell death via apoptosis.[106] MDSC can also influence the antigen presentation of DC and increase the proliferation of T_reg, promoting tumor growth in HCC[107] and CCA.[108] In CCA, CAF recruit MDSC to the TME via C-C chemokine ligand 2 (CCL2), contributing to tumor growth and cancer stemness, which impacts the resistance of the tumor to cancer therapy.[109] [110] In this context, treatment-induced immunosuppression can be further aggravated through the IL-1β-dependent recruitment of suppressive myeloid populations and the disruption of CD8 T cell responses.[111] In both HCC and CCA, host genetic variations in TME-modulating mediators like IL-1β and the IL-8 pathway have been associated with both oncological and overall prognosis.[112] [113] [114]

TAM are comprised of different subtypes that are either proinflammatory or anti-inflammatory with tissue-restorative functions.[115] They display a high plasticity and can be repolarized by the surrounding environment to serve the needs of the immune system. Tumors often take advantage of the pro-regenerative properties of TAM, which can be induced by cytokines such as IL-10, IL-4, and IL-13,[116] to promote angiogenesis, tumor proliferation, and metastasis.[117] [118] Polarization of TAM is also influenced by tumor-secreted molecules like the sonic hedgehog protein or succinate and by immune cells like T_reg or MDSC through the release of IFN-γ or downregulation of the signal transducer and activator of transcription 3 (STAT3) pathway.[119] In HCC, strong expression of PD-L1 on TAM and a consequential suppression of the T cell response have been shown to result in poor prognosis for patients.[107] [120] This may promote resistance of tumors to ICI therapy. Infiltration of TAM has been associated with disease progression in CCA patients as well due to activation of STAT3, and subsequent tumor proliferation.[121] Activation of STAT3 also causes the production of immunosuppressive cytokines like TGF-β, IL-17, and vascular endothelial growth factor (VEGF), contributing to ICI resistance.[122] [123] The immunosuppressive properties of TAM and their role in resistance to checkpoint therapy make them a possible target to overcome ICI resistance.[124]

CAF are abundant in the tumor stroma and are involved in remodeling of the extracellular matrix in the TME, thus playing an essential role in primary liver cancer as HCC often arises from a fibrotic, premalignant microenvironment while in highly desmoplastic CCA, the fibrous tissue develops in parallel with the tumor.[125] Mainly originating from activated hepatic stellate cells (HSC),[126] they promote tumor cell proliferation and orchestrate an immunosuppressive TME.[127] [128] Myofibroblastic HSC and CAF promote disease progression and tumorigenesis in both CCA and HCC.[129] [130] Interestingly, subpopulation analysis also revealed HSC with tumor-suppressing characteristics during hepatocarcinogenesis.[130]

In addition to immunosuppressive cells and cytokines produced in the TME, alternative inhibitory immune checkpoints like TIM-3 and LAG-3 can promote resistance to ICI therapy.[131] TIM-3 was found to be upregulated on TAM in the TME due to TGF-β exposure,[132] suggesting an alternative route of checkpoint inhibition used by cancer cells that would not be covered by PD-1/PD-L1 or CTLA-4 ICI therapy. Coexpression of LAG-3 and PD-1 on tumor-infiltrating lymphocytes results in a cooperative immunosuppressive effect[133] that could be upheld to some degree even after ICI monotherapy targeting PD-1/PD-L1 resulting in resistance. As LAG-3 and TIM-3 are upregulated and related to poor prognosis in HCC patients, it is relevant to consider this cause of resistance to ICI therapies.[134] [135]

 

MissingLinkText

Liver-Specific Mechanisms

The unique symbiosis of the liver with the gut and its microbiome, also referred to as the gut–liver axis, requires an intricate balance of immune surveillance and self-tolerance in the liver.[136] It is constantly exposed to diverse microorganisms, antigens, and microbial products through the portal vein, which demands complex regulation of the immune system to eliminate pathogens while avoiding autoimmune responses.[137] Consequently, macrophages in the (healthy) liver, particularly liver-resident Kupffer cells, are equipped to support immunosuppression.[138] Similarly, DC located in the liver have a lower expression of co-stimulatory molecules and thus a lower capacity to activate T cells.[137] [139] Liver tumors can use this to evade the immune system and limit the effect of potential immunotherapy treatments, ultimately causing resistance to ICI.

Most cases of primary liver cancer evolve due to an underlying liver disease—HCC most often on the background of fibrosis and cirrhosis caused by viral hepatitis, alcohol abuse or metabolic liver disease,[140] [141] and CCA due to inflammatory processes like primary sclerosing cholangitis (PSC) or parasites.[142] Notably, metabolic dysfunction-associated steatotic liver disease (MASLD) becomes more and more important, as it affects up to 38% of the global adult population.[143] MASLD can range from simple steatosis to MASH (metabolic dysfunction-associated steatohepatitis) with its characteristic hepatic inflammation, which may progress to fibrosis or cirrhosis and is tightly linked with obesity, type 2 diabetes, hypertension, and other cardiovascular diseases.[144] [145] Especially severe fibrosis embodies a high-risk factor for the development of primary liver tumors, at least in part due to the activation of fibroblasts with tumor-promoting function in both HCC and CCA.[125] The distinct adaptations of the hepatic immune microenvironment in viral versus non-viral etiologies[146] may also affect the response to ICI therapy and emerging evidence suggests that non-viral HCC may be accompanied by reduced ICI therapy efficacy.[147] [148] [149] Mechanistically, we and other groups have demonstrated fundamental changes in the hepatic immune microenvironment of both lymphoid[150] [151] [152] [153] and myeloid compartments[154] [155] [156] in MASLD mouse models and patients.[130] [157] [158] As commonly available ICIs focus on amplifying CTL function,[159] lymphocytes are a central spotlight in this context. The accumulation of tissue-resident memory T cells as well as autoaggressive exhausted CTL have been shown to drive inflammation and fibrosis in the livers of preclinical MASH models as well as MASH patients.[150] [151] Indeed, therapeutic anti-PD1 treatment led to the expansion of these exhausted CTL in the tumors of MASH-HCC-bearing mice but failed to ensure tumor control. Strikingly, prophylactic treatment increased HCC incidence, highlighting the important protective mechanisms of inhibitory checkpoints.[160] Even in PD-1 responsive liver cancer mouse models, efficacy was abrogated by diet-induced MASLD/MASH, which was caused by diet-associated impaired CTL metabolism and motility. Remarkably, this effect could be rescued by additional metformin treatment.[161] CD4+ T cells also play a role in ICI efficacy[162] as evidenced by the MASH-inducing methionine-deficient diet, which leads to loss of hepatic CD4+ T cells aggravating HCC development.[153] Fittingly, subgroup-specific meta-analyses of multiple randomized controlled trials demonstrated a higher survival benefit for patients with viral HCC compared to non-viral etiology.[149] [160] However, the matter is more complicated, as patients of non-viral etiology actually seem to benefit from double ICI therapy (anti-PD-L1 plus anti-CTLA-4).[163] Furthermore, it is not clear how many patients with non-viral HCC actually suffer from MASLD. Nevertheless, the impact of the underlying liver disease on the response to ICI therapy is still plausible, and further research is necessary to illuminate on this matter.[164] [165]

MASLD is tightly connected to obesity and changes in the microbiome, which might also influence response to ICI. Obesity has already been linked to limited tumor control due to leptin-dependent T cell exhaustion in a genetic obesity mouse model[166] and tumor cells of mice fed with a high-fat diet increased lipid uptake, which was followed by metabolic reprogramming and impaired CTL function.[167] Furthermore, metabolic activation of B cells also leads to tumor-promoting dysfunctional T cell responses in this context.[152] Interestingly, leptin-dependent T cell exhaustion increased response to anti-PD-1 therapy[166] and this effect can also be seen in patients with non–small-cell lung cancer (NSCLC) and melanoma.[168] Microbial dysbiosis has also been reported in patients not responding to ICI for many types of cancers including HCC and CCA,[169] [170] which leads to immunosuppressive rather than antitumor immune responses. In addition, microbial diversity declined in non-responders over the course of treatment,[169] and antibiotic treatment was associated with shorter survival times.[171]

 

MissingLinkText

 

MissingLinkText

“Ready-to-Use” Combination Therapy to Overcome Primary Resistance

As described earlier, single-agent PD-(L)1 inhibitor therapies generate lasting antitumor response in subgroups of patients with advanced HCC[18] [19] [172] but do not demonstrate a significant survival benefit for the overall treatment population compared with tyrosine kinase inhibitors.[20] [173] Combining ICI with other, already existing antitumor agents for primary liver cancer represents an accessible choice to overcome primary resistance to ICI therapy ([Table 2]).

Table 2 Selected phase III ICI combination therapy trials in advanced or unresectable HCC and CCA

Trial	Time of recruitment	Treatment	Line of therapy	Participants	Etiology		Disease stage		Median OS (mo)	Median PFS (mo)	ORR (%)	DCR (%)	Ref.
				n	Viral (%)	Nonviral (%)	EHD (%)	BCLC C (%)
ICI plus ICI
HIMALAYA (NCT03298451)	10/2017–06/2019	STRIDE (durvalumab plus tremelimumab)	1st-line HCC	393	59	41	53.2	80.4	16.43e (sorafenib)	3.78	20.1	60.1	[185]
		Durvalumab		389	58.1	41.9	54.5	79.4	16.56	3.65	17.0	54.8
		Sorafenib		389	57.3	42.7	52.2	83.0	13.77	4.07	5.1	60.7
ICI plus MKI (or anti-VEGF antibodies)
IMBrave150 (NCT03434379)	03/2018–01/2019	Atezolizumab plus bevacizumab	1st-line HCC	336	70	30	63	82	NRf	6.8f	27.3f	73.6	[199]
		Sorafenib		165	68	32	56	81	13.2	4.3	11.9	55.3
COSMIC-312 (NCT03755791)	12/2018–08/2020	Atezolizumab plus cabozantinib	1st-line HCC	432	60	39	54	68	15.4	6.8 e	11	78	[203]
		Sorafenib		217	60	40	56	67	15.5	4.2	4	65
		Cabozantinib		188	73	37	54	65	n.a.	n.a.	6	84
ORIENT-32 (NCT03794440)	02/2019–01/2020	Sintilimab + IBI305 (bevacizumab biosimilar)	1st-line HCC	380	96	4	73	85	NRg	4.6g	21%g	72	[201]
		Sorafenib		191	98	2	75	86	10.4	2.8	4%	64
LEAP-002 (NCT03713593)	01/2019–04/2020	Pembrolizumab plus lenvatinib	1st-line HCC	395	63	37	63	78	21.2a	8.2	26.1	81.3	[204]
		Placebo plus lenvatinib		399	61	39	61	76	19.0	8.1	17.5	78.4
CARES-310 (NCT03764293)	06/2019–03/2021	Camrelizumab plus rivoceranib	1st-line HCC	272	84	15	64	86	22.1c	5.6c	25c	78	[205]
		Sorafenib		271	84	17	66	85	15.2	3.7	6	54
ICI plus chemotherapy
TOPAZ-1 (NCT03875325)	02/2019–12/2020	Durvalumab plus gemcitabine and cisplatin	1st-line CCA	341	n.a.		55.7 (iCCA)	88.9 (metastases)	12.8d	7.2f	26.7	85.3	[221]
		Placebo plus gemcitabine/cisplatin		344			56.1 (iCCA)	83.1 (metastases)	11.5	5.7	18.7	82.6
KEYNOTE-966 (NCT04003636)	10/2019–06/2021	Pembrolizumab plus gemcitabine/cisplatin	1st-line CCA	533		60 (iCCA)	89 (metastases)	12.7b	6.5a	29	75	[223]
						Placebo plus gemcitabine/cisplatin		536	n.a.		58 (iCCA)		88 (metastases)	10.9	5.6	29	76

Abbreviations: BCLC, Barcelona Clinic Liver Cancer criteria; CCA, cholangiocarcinoma; EHD, extrahepatic disease; DCR, disease-control rate; HCC, HCC, hepatocellular carcinoma; ICI, immune checkpoint inhibitor; n.a., not applicable; NR, not reached; ORR, objective response rate; OS, overall survival; PFS, progression-free survival, STRIDE, single tremelimumab regular interval durvalumab; MKI, multikinase inhibitor.

Statistics: one-sided ^a p< 0.05, ^b p < 0.01, ^c p < 0.0001; two-sided ^d p < 0.05, ^e p < 0.01, ^f p < 0.001, ^g p < 0.0001.

Combination of Immune Checkpoint Inhibitors

To further accelerate antigen-mediated CTL cytotoxicity, blocking additional inhibitory checkpoint molecules and stimulating activating ones[174] are standard strategies regarding combination therapy. The most commonly combined immune checkpoint antibodies in liver cancer are anti-PD-L1 and anti-CTLA-4. The rationale behind this combination is that blockage of the PD-1/PD-L1 pathway does not necessarily lead to antitumor immunity, if PD-1+ CTLs are not present in the tumor.[34] Furthermore, in case they are present, their actions might be counteracted by immunosuppressive T cells such as T_reg. For instance, single anti-PD-1 treatment resulted in expansion of exhausted CTL (PD-1 + , LAG-3 + , TIGIT + ) but failed to induce tumor control in a HCC mouse model.[175] Furthermore, CTLA-4 blockade increases activation of CTL in the lymph node and therefore the probability of cancer antigen–specific CTL infiltrating the TME[34] ([Fig. 1]). The synergistic effects of anti-CTLA—direct enhancement of effector T cell function as well as inhibition of immunosuppressive T_reg and indirect higher probability of DC maturation during the priming phase[34] [174] [176]— in conjunction with anti-PD-1/PD-L1 blockade in the immune effector phase have been verified as a therapeutic option in various advanced cancers including melanoma, colon, and lung cancer.[177] [178] [179] [180]

First results on anti-PD-1/CTLA-4 combination therapy originated from the randomized phase I/II trial CheckMate 040, testing safety and efficacy of three distinct nivolumab plus ipilimumab sequences in a HCC patient cohort previously treated with sorafenib.[18] All study arms showed promising ORR of approximately 30%, with the highest complete response rates and mOS (22.8 months) observed for patients receiving four doses of 1 mg/kg nivolumab plus 3 mg/kg ipilimumab for every 3 weeks followed by 240 mg nivolumab every 2 weeks (study arm A).[181] At this time, approved second-line MKI therapy demonstrated only a maximum of 10.6 months of mOS,[9] [10] [11] resulting in accelerated approval of nivolumab combined with ipilimumab for second-line advanced HCC therapy in the United States.[182] The improvement of ORR and OS may directly correlate to increasing dosages of ipilimumab, which coincides with higher rates of adverse effects. Nevertheless, the benefit–risk profile still favors the combination therapy with higher anti-CTLA-4 dosage.[183] In another phase I/II trial, the STRIDE (single-dose tremelimumab [anti-CTLA-4] with regular interval durvalumab [anti-PD-L1]) regime demonstrated highest ORR (24%), mOS of 18.7 months, and most prominent increase of proliferating peripheral CTL 2 weeks after starting therapy in advanced HCC patients.[184] The following randomized, controlled phase III trial (HIMALAYA), which tested STRIDE and durvalumab monotherapy against standard of care sorafenib in treatment-naive advanced HCC, demonstrated superior OS of STRIDE against sorafenib (16.43 vs. 13.77 months) and noninferiority of durvalumab monotherapy to sorafenib.[185] Following this trial, STRIDE received FDA approval and was included as a first-line option for advanced HCC in clinical practice guidelines.[186] [187] [188]

In noncontrolled phase I/II studies on pretreated CCA, the combination of nivolumab/ipilimumab surprisingly did not cause superior ORR and mOS (23 and 5.7 months, respectively)[189] to nivolumab monotherapy (22 and 14.2 months).[190] This may have resulted from differences in study ORR assessment and patient exclusion criteria[189] as well as relatively low doses of ipilimumab (1 vs. 3 mg/kg in pretreated HCC[181]). In another phase II study including Asian patients with advanced and pretreated CCA, combination therapy of durvalumab and tremelimumab in comparison to durvalumab monotherapy managed to obtain moderately higher ORR (10.8 vs. 4.8%) and a comparable safety profile.[191] Further studies are required to access the leverage of combined ICI therapy in CCA.

 

MissingLinkText

Combining ICI and Targeted Therapy (TKI or Antiangiogenic Drugs)

Tumor angiogenesis is one of the essential hallmarks of cancer.[192] Hypoxia during tumor growth triggers expression of proangiogenic factors such as VEGF by upregulation of hypoxia-inducible factor proteins and causing neoangiogenesis.[193] Additionally, VEGF facilitates essential immunosuppressive functions by undermining leukocytes–endothelial cell adhesion and DC maturation, impairing CTL proliferation and function by promoting their exhaustion and increases T_reg infiltration.[194] Normalizing this VEGF-suppressed TME by using inhibitors of VEGF (antibodies, e.g., bevacizumab or VEGFR-targeting MKIs, e.g., sorafenib or lenvatinib) might synergize with anti-PD-1/PD-L1 therapy to more effectively unleash CTL-mediated cancer cell killing.[195] Another advantage of this combination therapy might be that ICI counteracts intratumoral PD-L1 upregulation caused by antiangiogenic therapy.[196] Anti-VEGF therapy itself might therefore create an even more immunosuppressive TME, which could be unleashed by ICI therapy. Combinations of antiangiogenic and ICI therapy have already been successfully introduced in other solid cancers such as renal cell carcinoma.[197] [198]

Combination of the PD-L1 inhibitor atezolizumab with bevacizumab demonstrated longer PFS than atezolizumab alone in a phase Ib study with previously untreated advanced HCC patients.[172] Its successor, the randomized phase III trial, IMbrave150 demonstrated significantly reduced risk to die in the patient groups treated with combination therapy, with significantly longer PFS, higher ORR, and 20% more disease control until the time of first analysis.[199] The significant survival benefit of anti-PD-L1 plus anti-VEGF therapy was confirmed in the updated data analysis from 2022[200] and with the China-based ORIENT-32 phase III trial, which also reported significantly prolonged OS and PFS when treated with anti-PD-L1 sintilimab and IBI305 (bevacizumab biosimilar).[201] In addition, the randomized phase III IMbrave050 trial demonstrated that adjuvant treatment with the atezolizumab/bevacizumab combination after resection or ablation improved recurrence-free survival versus active surveillance,[202] further highlighting the growing impact of ICI in curative treatment settings.

Because ICI combination with anti-VEGF antibodies was successful, it seemed evident to combine ICI with TKI, as they already have a significant beneficial effect on their own and block more pathways than VEGFR1/2 alone. Surprisingly, atezolizumab in combination with cabozantinib (COSMIC-312), although demonstrating significantly prolonged PFS, failed to improve OS and caused more treatment-associated adverse effects.[203] Along the same lines, the combination of pembrolizumab and lenvatinib in LEAP-002 failed to meet the prespecified boundaries for superiority in both OS and PFS.[204] The first trial showing significant advantages for the combination of ICI and TKI over TKI alone for both OS and PFS was the randomized, open-label phase III CARES-310 trial, comparing dual therapy of anti-PD-1 antibody camrelizumab with VEGFR2-targeting TKI rivoceranib (also known as apatinib) with sorafenib alone.[205] Here, combination therapy significantly prolonged mOS (22.1 vs. 15.2 months) and PFS (5.6 vs. 3.7 months). The ORR for the combination therapy was 25% and the disease control rate was 78% (vs. 54%). Just recently, combination of nivolumab and regorafenib demonstrated an impressive 1-year survival of 80.5% and ORR of 30.5% in a multicenter, single-arm phase II study including treatment-naive patients with advanced HCC,[206] clearing the way for possible future first-line treatments.

Although the efficacy of single-agent antiangiogenic[207] or ICI therapy in CCA remains limited, their combination created some encouraging results. For example, in a phase II trial, which included 32 patients with advanced CCA, treatment with pembrolizumab and lenvatinib in second-line resulted in an ORR of 25% and mOS of 11 months, which exceeded the results from monotherapy trials.[208]

 

MissingLinkText

Combination of ICI and Chemotherapy

Conventional chemotherapy is generally not recommended for HCC treatment, as HCC is resistant to the most common regimes and chemotherapy may aggravate underlying cirrhosis, leading to inconclusive or even negative survival benefits.[209] In comparison, Gem/Cis has been the standard first-line chemotherapy for patients with advanced CCA since the ABC-02 trial in 2010.[7]

While platinum-based chemotherapeutics mainly take effect by inducing apoptosis due to DNA strand breaks,[210] they have immunostimulatory properties as well.[211] [212] Cisplatin has been shown to increase the expression of MHC class I antigens on cancer cells and tumor-associated DC, recruit effector cells to the TME, increase cytolytic activity of CTL, and reduce the infiltration of immunosuppressive cells.[211] Additionally, gemcitabine may reduce the number of MDSC in tumor-bearing mice.[213] Since the TME of CCA has been described as mainly immunosuppressive with high infiltration of immunosuppressive cells or immune-exclusive with low T cell infiltration and low major histocompatibility complex (MHC)-I/PD-L1 expression,[214] the combination of immune checkpoint inhibition with Gem/Cis or other approved chemotherapeutics has been recognized as a successful antitumor concept. Furthermore, the concept was already proven in other advanced tumors such as NSCLC[215] and triple-negative breast cancer.[216]

Therefore, different combinations of ICI and chemotherapy have been evaluated in early-phase clinical trials throughout the last years.[217] [218] [219] [220] The most promising one tested three different sequences of Gem/Cis plus durvalumab alone or with tremelimumab. Notably, patients with immediate combination of Gem/Cis with durvalumab alone or durvalumab plus tremelimumab displayed high objective responses of approximately 70%.[220] While adding tremelimumab to the regimen achieved no additional benefit in ORR and OS, the combination of durvalumab and Gem/Cis has been further explored in the phase III TOPAZ-1 trial,[221] which tested the anti-PD-L1 drug durvalumab with chemotherapy (n = 341) compared to placebo with chemotherapy (n = 344) in patients with advanced CCA. The OS over 24 months was 24.9% for the durvalumab cohort and 10.4% for the placebo cohort, with an ORR of 26.7 and 18.7%, respectively. The median PFS for durvalumab was 7.2 months compared to 5.7 months in patients treated with placebo. The achieved results and safety profiles were comparable with above-mentioned ICI monotherapy trials in HCC. Because of these encouraging results, TOPAZ-1 became the new standard therapy in advanced CCA.[222] Results from KEYNOTE-966, a phase III trial testing the combination of pembrolizumab and Gem/Cis in first-line setting in CCA, were similarly encouraging.[223] Consequently, combining ICIs with chemotherapy became standard of care for advanced CCA.[224]

 

MissingLinkText

 

MissingLinkText

Mechanisms of Acquired (Secondary) Resistance

Tumors that initially respond to ICI therapy often develop acquired or secondary resistance through adaptive mechanisms.[225] Considering the fact that due to availability of advanced combinations more liver cancer patients are responding to ICI therapy, it can be expected that a substantial amount of patients will also have to deal with acquired resistance.[48] As ICI combination therapies have only been used in standard settings so far, rates of acquired resistance have not yet been widely reported for liver cancer. In other tumor types, acquired resistance has been shown to affect up to 65% of patients in up to 4 years of follow-up.[225]

The specific mechanisms driving acquired resistance are in many aspects still elusive—especially regarding primary liver cancer—but are to some degree overlapping with components of primary resistance.[226] Collected clinical reports suggest reduced TAA availability, disrupted antigen presentation, altered IFN-γ signaling, promotion of an excluded/immunosuppressive TME, and upregulation of (alternative) checkpoints as possible mechanisms.[225] In addition, emerging data suggest that a considerable proportion of patients develop anti-drug antibodies against certain ICI.[227] For example, 28% of tested patients developed antibodies against atezolizumab during IMbrave150,[146] while less than 5% of patients developed antibodies against durvalumab or tremelimumab during the HIMALAYA trial.[185] While the impact of these drug-neutralizing antibodies on primary and secondary resistance is not completely understood, they might interfere with the treatment efficacy, as patients who develop antibodies against atezolizumab early during therapy are less likely to benefit.[146] [228]

These mechanisms are often driven by escape mutations. For example, tumors can lose the encoding sequences for key TAA related to the initial ICI response by sub-clone elimination or genomic alterations.[229] [230] In consequence, expanding adapted tumor clones are more protected from antigen-associated CTL killing. Furthermore, new mutations can favor a less immunogenic TME. Alterations of beta-2-microglobulin (B2M) lead to reduced or disturbed MHC class I expression on tumor cells, which hinders effective antigen recognition by APC, and are common findings in lung cancer and melanoma patients with acquired resistance.[231] [232] [233] In line with this, mutations in Janus kinase 1 and 2 (JAK1/2) disrupt the IFN-γ (released from effector T cells) signaling pathway in tumor cells, reducing the expression of MHC class I and PD-L1 and thereby hindering tumor cell killing.[234] [235] Another mechanism for acquired resistance is the immunosuppressive reshaping of the TME by immunosuppressive cytokines. Loss of tumor suppressor PTEN or activity of the Wnt/β-catenin pathway, which are also linked to primary resistance (see above), can lead to immunosuppressive cytokine production and defective DC priming.[86] [236] Upregulation of alternative immune checkpoints such as TIM-3 or LAG-3 contributes to T cell exhaustion[237] [238] and their expression on (potential) APC can negatively influence the antigen presentation mechanisms.[239] [240] [241]

Since data on acquired resistance are still sparse in liver cancer, the question remains whether (and how) to treat patients after acquired therapy failure. For this, a distinct analysis and knowledge of the therapy-altered TME is likely to be key. In clinical practice, re-challenge with a different regimen of ICI after failure of first-line ICI therapy in HCC is oftentimes considered and demonstrated (some) efficacy.[242] Alternatively, novel combination therapies with the possibility to completely eliminate the tumor might be able to prevent acquired resistance altogether.

 

MissingLinkText

The Future of ICI Therapy—How to Heat up the TME

As discussed in the previous paragraphs, single ICI therapy most likely shows benefit for patients when the tumor has a hot TME. As the majority of primary liver cancer displays an immune-negative TME,[214] [243] which can be caused by various altered and dysregulated processes during the cancer-immunity cycle,[244] altering these hallmark steps and reshaping the TME using additional agents might open a window of opportunities for ICI to work its magic.[52] [245] [246] Recently, established double-combination therapies have already shown promising effects (see above), but current research suggests to explore even more complex therapy regimes. Here, we focus on the most prominent developments and provide an overview on preclinically and clinically explored therapeutic options ([Fig. 1]). However, as a note of caution, HCC — and to some extent also CCA — develop in a chronically injured, oftentimes fibrotic or cirrhotic liver; any attempt to reinforce inflammation (to “heat up” the TME) needs to consider the risk of aggravating liver inflammation and fibrosis, that is, aggravating the underlying liver disease.[115]

Inducing Immunogenic Cell Death

Immunologically cold tumors are characterized by a lack of TAA and APC-recruiting danger signals and therefore show absence of overall immune cell infiltration, which in turn makes beneficial ICI therapy highly unlikely.[50] While the main goal of established primary liver cancer treatment options, such as chemotherapeutics, targeted therapy, and local treatment, is the reduction of tumor burden, they also have been shown to stimulate tumor-specific immune responses by immunogenic cell death (ICD).[247] ICD is a form of regulated cell death, which triggers adaptive immune responses in the host and is characterized by simultaneous release of TAA as well as immunostimulatory DAMP (such as heat shock proteins, high-mobility-group protein B1, and adenosine triphosphate), which recruit DC and other APC to the tumor.[248]

The possibilities of radiation therapy include SBRT (stereotactic body radiation), SIRT (selective internal radiotherapy), and transarterial radioembolization. While liver toxicity is a limiting factor especially for patients with underlying liver disease, local application is a substantial option for patients with primary liver cancer.[4] Apart from the induced DNA damage to the tumor cells, which is the primary effect, radiation has been shown to improve TAA and DAMP release as well as type 1 IFN production, followed by DC infiltration and maturation and increased CTL infiltration.[249] Furthermore, radiation can facilitate the upregulation of MHC class I expression.[250] Some encouraging results have already been detected for the combination of nivolumab/SIRT and nivolumab/ipilimumab/SBRT in HCC.[251] [252] Notably, radiation can also have immunosuppressive effects on the TME, which we will discuss later.

Conventional chemotherapy, especially platin-based therapy regularly used in CCA treatment, can be an effective inducer of ICD as well.[253] In HCC, local chemotherapy application to the tumor via transarterial chemoembolization (TACE) remains a standard treatment option for intermediate stages and has been shown to upregulate proinflammatory pathways.[254] In this regard, the EMERALD-1 phase III trial recently demonstrated significantly prolonged PFS when TACE-eligible patients with unresectable HCC were additionally treated with durvalumab and bevacizumab, possibly laying the foundation for improved standard treatments of advanced HCC.[255] Other locoregional therapies—such as radio frequency or thermal ablation—also induce ICD characterized by the release of DAMPs like heat shock proteins,[256] [257] and combination therapy with ICI is being investigated in great depth in this regard.[254]

Oncolytic viruses (OVs) are another approach to induce ICD, engineered to exclusively infect and lyse tumor cells.[258] While there is, up to this point only, preclinical evidence for successful OV application in CCA, they have been used in clinical HCC trials.[259] The most prominent, JX-594 (commercially: Pexa-Vac), an oncolytic pox virus vaccine additionally expressing GM-CSF and β-galactosidase for APC recruitment, was shown to induce antibody-mediated cancer cell cytotoxicity and TC activation in a rabbit VX2 tumor model as well as in humans with various solid tumors.[260] While it also demonstrated dose-dependent improved survival in a dose-finding trial,[261] JX-594 did not improve survival as second-line therapy after HCC patients progressed on sorafenib, although increased TC responses were observed in the therapy arm.[262] Nevertheless, a combination with nivolumab to amplify ICI treatment efficacy is currently under investigation (NCT03071094).

 

MissingLinkText

APC Recruitment, Activation, and TC Priming

Following the release of TAA and DAMP, the recruitment and activation of APC are the next essential steps in the cancer immunity cycle. Cytokines, such as FMS-like tyrosine kinase 3 ligand (Flt3L), are able to attract DC, which can subsequently be activated by adjuvants, like toll-like receptor (TLR) agonists.[263] PolyIC, a synthetic TLR3 agonist, induces activation and maturation of conventional DC type 1[264] and is currently tested in combination with anti-PD-1 in HCC patients (NCT03732547). The TLR9 agonist CpG[265] has not yet been explored in clinical HCC, but intratumoral injection of CpG into orthotopic and ectopic HCC mouse models together with anti-OX40 significantly slowed down tumor growth and inhibited T_reg and MDSC infiltration to the tumor site while increasing CTL infiltration.[266] The CD40 receptor, which is expressed on activated APC, drives activation of CTL by engaging with its ligand CD40L, leading to optimized priming with clonal T cell expansion and CTL infiltration when combined with chemotherapy.[267] The combination of anti-PD1, CD40 agonist and gemcitabine/cisplatin chemotherapy, has been shown to significantly improve survival when compared with chemotherapy treatment alone in preclinical CCA models.[268] A similar combination is currently explored in a Phase 1/2 trial (NCT05849480).

 

MissingLinkText

Boost Infiltration of Immune Cells

In an excluded TME, immune cells linger at the border of the tumor and do not enter the tumor stroma, which is further exacerbated by reduced pH, hypoxia, and nutrient availability.[49] Treatment against VEGF, with antibodies or MKI, as well as TACE have shown to positively influence the chaotic angiogenesis of the TME, which helps immune cell infiltration.[269] In addition to other immune effects, yttrium-90 radioembolization has been shown to upregulate the chemokine C-C motif ligand 5 (CCL5) and chemokine C-X-C motif ligand 16 (CXCL16) pathway in the tumors of HCC patients, which led to boosted CTL and NK cell infiltration.[270]

The formation of a tumor immune barrier, containing CAF and secreted phosphoprotein 1 (SPP1)+ macrophages, at the tumor border of HCC patients correlates with reduced response to anti-PD-1 therapy[271] and, therefore, stroma-modifying therapy is an interesting approach for combination therapy. While the data on CAF therapy in liver cancer is still sparse, targeting CAF-specific proteins like fibroblast activation protein, repolarization of the myofibroblastic phenotype, and targeting of CAF-derived signals seems promising.[272] For example, combination of a CXCR4 inhibitor (receptor for CAF-produced CXCL12) and anti-PD-L1 reduced tumor growth in a mouse pancreatic cancer model,[273] and combination of TGF-β blockade and PD-L1 antibody therapy increased T cell infiltration into the tumors of immune-excluded mouse breast cancer models.[274]

 

MissingLinkText

Counteracting Immunosuppressive Adaptations

MKIs are well established as first- and second-line therapy options for patients with advanced HCC.[209] In a substantial proportion of selected patients with CCA, molecularly targeted therapy may be an option, with several approved drugs either targeting oncogenic fibroblast growth factor receptor 2 (FGFR2) fusions or gain-of-function variants of IDH1.[275] Their influence on the VEGFR pathway is thought to increase influx of T cells to the TME and patients with HCC already greatly benefit from the VEGF(R)-targeting therapy and ICI combination ([Table 2]). Nevertheless, preclinical HCC data also suggest immunosuppressive effects. Sorafenib promotes immunosuppression by PD-L1 upregulation and CXCR4- mediated infiltration of T_reg and M2-polarized macrophages.[276] In this case, treatment with anti-PD1 showed only additional effects when combined with sorafenib and anti-CXCR4 but not sorafenib alone, making a case for targeting immunosuppressive pathways and cells as an important feature of combination immunotherapy.[276] Furthermore, radiation therapy can also shape the TME in an immunosuppressive way.[263] For example, post-TACE TME analysis of HCC patients showed reduced numbers of infiltrating CTL and increase triggering receptor expressed on myeloid cells (TREM)2+ TAM compared to pre-TACE TME.[277] Therefore, if ICD is induced, immunosuppressive counterregulation might be a consequence. For example, the Flt3L-dependent infiltration of DC to the TME may be accompanied by T_reg influx.[278]

Hence, the importance of counteracting immunosuppressive cells has been widely discussed and future combination therapies have to address these issues. Combinations of anti-PD1 antibodies with anti-CTLA-4[34] or VEGF-inhibitors[195] have been shown to counteract T_reg and combining doxorubicin (commonly used in TACE) with a mitophagy-inducing drug also reshaped the TME towards more memory and effector T cells and less T_reg in a mouse model of HCC.[279]

Blocking immunosuppressive myeloid cells has also been explored in the field. An interesting preclinical example has been recently published: in an HCC mouse model, ferroptosis induction resulted in increased CTL infiltration which was counteracted by tumor cell PD-L1 upregulation. While combination with anti-PD-1 therapy did result in a modest survival benefit, only the combination of ferroptosis induction, anti-PD1, and blockade of C-X-C-chemokine receptor 2 (CXCR2)-mediated MDSC infiltration led to a long-lasting antitumor response.[280] Also, the combination of anti-CXCR2 and anti-PD-1 was shown to be very effective in a preclinical model of steatosis-induced HCC.[281] This combination is currently under clinical investigation in HCC.[282] Colony-stimulating factor 1 (CSF1) blockade also represents a new combination target currently approached in liver cancer therapy (NCT05438420)—it has been shown to prevent migration and activation of TAM and enhanced antitumor immunity when combined with anti-PD-L1 in an osteopontin-overexpressing HCC mouse model.[283] Similarly, PD-L1 expressing TAM in concert with MDSC facilitated tumor growth in a murine CCA model and only inhibition of TAM infiltration (via CSF1R blockade) combined with MDSC depletion resulted in response to PD-1 blockade.[284]

TGF-β is one of the most prominent cytokines to promote tumor growth and immunosuppressive functions in the TME,[285] and TGF-β inhibitors have been hypothesized to make the TME more approachable for other immunotherapies. Bintrafusp alfa, a bifunctional fusion protein combining anti-PD-L1 with a “TGF-β-trap,” has shown some favorable results in second-line setting[286] for CCA. In contrast, a number of clinical trials with TGF-β inhibitor and ICI combination failed to show enhanced antitumor immunity — the combination with ICD inducers might be essential for this therapy to work.[287]

The expression of alternative checkpoints such as TIM-3 and LAG-3 also contributes to an immunosuppressive TME.[225] Recently, combination of nivolumab and relatlimab (anti-LAG-3) demonstrated favorable PFS compared to nivolumab monotherapy in patients with advanced treatment-naive melanoma in a phase III trial.[288] Compared to this, encouraging trial data on anti-TIM-3 are limited. First results on TIM-3 antibody monotherapy in a phase I trial in advanced solid cancers showed only little response.[289] In advanced MSI-H/dMMR tumors (phase Ib), monotherapy as well as combination with anti-PD-(L)1 showed surprisingly high response rates up to 45%.[290] Of note, responses were always more favorable if patients initially responded to anti-PD-(L)1 therapy, highlighting the potential use of alternative ICI therapy in acquired ICI resistance.[225] In primary liver cancer, combination of anti-TIM3 with anti-PD1 is currently under investigation (NCT03680508).

 

MissingLinkText

 

MissingLinkText

Outlook—Decision-Making Based on the TME and Challenges to Overcome

Looking back on the sheer amount of options for combination therapy, we want to emphasize on the importance of hypothesis-driven and evidence-based decisions to choose adequate therapies for individual primary liver cancer patients, which is in line with what other authors proposed.[246] [291] Given the fact that advanced combinations of three substances or more are currently under investigation, the potential increase in treatment-related toxicity, immune-adverse events, and therapy costs make it even more important to identify groups of patients who are in need of complex combinations to achieve successful antitumor immunity. We and others[52] [246] propose the composition of the TME to be one of the most important indicators for rational therapy decisions. While patients with a cold, immune-deserted TME might benefit from ICD induction, patients with an immunosuppressive TME might benefit from MDSC blockade. Until we can use this kind of decision-making in clinical practice, the most pressing matter to explore is not only possible therapies but especially biomarkers to validate therapy decisions. For personalized TME-based therapy decisions, in-depth analysis of the individual tumor with DNA mutation variances, RNA and protein expression profiles as well as spatial distribution of tumor cells, CAFs, and immune cells would be necessary—not only once, but repeatedly to keep track of changes occurring in response to therapy.[246] Understandably, it is currently not possible to apply these techniques to every liver cancer patient treated with ICI. Therefore, one of the most important challenges for the future of ICI combination therapy is the validation of predictive TME-based biomarkers.[292] [293] Fortunately, recently published studies already started to address these demands.[206] [294]

In summary, ICI combination therapies are able to overcome low response rates and survival benefits of ICI monotherapy and revolutionized the treatment options for patients with advanced primary liver cancer. Personalized treatment decisions based on TME-related biomarkers might further improve prediction of therapy efficacy and thereby increase therapy responses and reduce unnecessary treatments (and their side effects).

 

MissingLinkText

 

MissingLinkText

Conflict of interest

F.T.'s lab has received research funding from AstraZeneca, MSD, and Gilead (funding to the institution). Other authors have nothing to declare.

• References

• 1 Sung H, Ferlay J, Siegel RL. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71 (03) 209-249
• 2 Rumgay H, Arnold M, Ferlay J. et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol 2022; 77 (06) 1598-1606
• 3 Arnold M, Abnet CC, Neale RE. et al. Global burden of 5 major types of gastrointestinal cancer. Gastroenterology 2020; 159 (01) 335-349.e15
• 4 Lurje I, Czigany Z, Bednarsch J. et al. Treatment strategies for hepatocellular carcinoma – a multidisciplinary approach. Int J Mol Sci 2019; 20 (06) 1465
• 5 Forner A, Vidili G, Rengo M, Bujanda L, Ponz-Sarvisé M, Lamarca A. Clinical presentation, diagnosis and staging of cholangiocarcinoma. Liver Int 2019; 39 (Suppl. 01) 98-107
• 6 Llovet JM, Ricci S, Mazzaferro V. et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359 (04) 378-390
• 7 Valle J, Wasan H, Palmer DH. et al; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362 (14) 1273-1281
• 8 Kudo M, Finn RS, Qin S. et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018; 391 (10126): 1163-1173
• 9 Bruix J, Qin S, Merle P. et al; RESORCE Investigators. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 389 (10064): 56-66
• 10 Abou-Alfa GK, Meyer T, Cheng AL. et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med 2018; 379 (01) 54-63
• 11 Zhu AX, Kang YK, Yen CJ. et al; REACH-2 Study Investigators. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019; 20 (02) 282-296
• 12 Qin S, Li Q, Gu S. et al. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol 2021; 6 (07) 559-568
• 13 Lamarca A, Palmer DH, Wasan HS. et al; Advanced Biliary Cancer Working Group. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol 2021; 22 (05) 690-701
• 14 Ledford H. Melanoma drug wins US approval. Nature 2011; 471 (7340) 561
• 15 Hanaizi Z, van Zwieten-Boot B, Calvo G. et al. The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Eur J Cancer 2012; 48 (02) 237-242
• 16 Raedler LA. Opdivo (nivolumab): second PD-1 inhibitor receives FDA approval for unresectable or metastatic melanoma. Am Health Drug Benefits 2015; 8 (Spec Feature): 180-183
• 17 Sul J, Blumenthal GM, Jiang X, He K, Keegan P, Pazdur R. FDA approval summary: pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1. Oncologist 2016; 21 (05) 643-650
• 18 El-Khoueiry AB, Sangro B, Yau T. et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017; 389 (10088): 2492-2502
• 19 Zhu AX, Finn RS, Edeline J. et al; KEYNOTE-224 Investigators. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 2018; 19 (07) 940-952
• 20 Yau T, Park JW, Finn RS. et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 2022; 23 (01) 77-90
• 21 Finn RS, Ryoo BY, Merle P. et al; KEYNOTE-240 Investigators. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, Phase III trial. J Clin Oncol 2020; 38 (03) 193-202
• 22 Burnet M. Cancer; a biological approach. I. The processes of control. BMJ 1957; 1 (5022) 779-786
• 23 Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3 (11) 991-998
• 24 Huntington ND, Cursons J, Rautela J. The cancer-natural killer cell immunity cycle. Nat Rev Cancer 2020; 20 (08) 437-454
• 25 Speiser DE, Chijioke O, Schaeuble K, Münz C. CD4⁺ T cells in cancer. Nat Cancer 2023; 4 (03) 317-329
• 26 Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013; 39 (01) 1-10
• 27 Funes SC, Manrique de Lara A, Altamirano-Lagos MJ, Mackern-Oberti JP, Escobar-Vera J, Kalergis AM. Immune checkpoints and the regulation of tolerogenicity in dendritic cells: implications for autoimmunity and immunotherapy. Autoimmun Rev 2019; 18 (04) 359-368
• 28 Starzer AM, Preusser M, Berghoff AS. Immune escape mechanisms and therapeutic approaches in cancer: the cancer-immunity cycle. Ther Adv Med Oncol 2022; 14: 17 588359221096219
• 29 Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov 2018; 8 (09) 1069-1086
• 30 Wojtukiewicz MZ, Rek MM, Karpowicz K. et al. Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners. Cancer Metastasis Rev 2021; 40 (03) 949-982
• 31 Pentcheva-Hoang T, Egen JG, Wojnoonski K, Allison JP. B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity 2004; 21 (03) 401-413
• 32 Azarov I, Helmlinger G, Kosinsky Y, Peskov K. Elaborating on anti CTLA-4 mechanisms of action using an agent-based modeling approach. Front Appl Math Stat 2022; 8: 993581
• 33 Sobhani N, Tardiel-Cyril DR, Davtyan A, Generali D, Roudi R, Li Y. CTLA-4 in regulatory T cells for cancer immunotherapy. Cancers (Basel) 2021; 13 (06) 1440
• 34 Kudo M. Scientific rationale for combination immunotherapy of hepatocellular carcinoma with anti-PD-1/PD-L1 and anti-CTLA-4 antibodies. Liver Cancer 2019; 8 (06) 413-426
• 35 Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med 2016; 375 (18) 1767-1778
• 36 Pauken KE, Torchia JA, Chaudhri A, Sharpe AH, Freeman GJ. Emerging concepts in PD-1 checkpoint biology. Semin Immunol 2021; 52: 101480
• 37 Liu J, Chen Z, Li Y, Zhao W, Wu J, Zhang Z. PD-1/PD-L1 checkpoint inhibitors in tumor immunotherapy. Front Pharmacol 2021; 12: 731798
• 38 Ziogas DC, Theocharopoulos C, Lialios P-P. et al. Beyond CTLA-4 and PD-1 inhibition: novel immune checkpoint molecules for melanoma treatment. Cancers (Basel) 2023; 15 (10) 2718
• 39 Sauer N, Szlasa W, Jonderko L. et al. LAG-3 as a potent target for novel anticancer therapies of a wide range of tumors. Int J Mol Sci 2022; 23 (17) 9958
• 40 Wolf Y, Anderson AC, Kuchroo VK. TIM3 comes of age as an inhibitory receptor. Nat Rev Immunol 2020; 20 (03) 173-185
• 41 Sauer N, Janicka N, Szlasa W. et al. TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors. Cancer Immunol Immunother 2023; 72 (11) 3405-3425
• 42 FDA. Last Accessed May 15, 2024, at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-nivolumab-hcc-previously-treated-sorafenib
• 43 Kudo M, Finn RS, Edeline J. et al; KEYNOTE-224 Investigators. Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. Eur J Cancer 2022; 167: 1-12
• 44 Merle P, Kudo M, Edeline J. et al. Pembrolizumab as second-line therapy for advanced hepatocellular carcinoma: longer term follow-up from the Phase 3 KEYNOTE-240 trial. Liver Cancer 2023; 12 (04) 309-320
• 45 Qin S, Chen Z, Fang W. et al. Pembrolizumab versus placebo as second-line therapy in patients from Asia with advanced hepatocellular carcinoma: a randomized, double-blind, Phase III trial. J Clin Oncol 2023; 41 (07) 1434-1443
• 46 Marabelle A, Le DT, Ascierto PA. et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the Phase II KEYNOTE-158 study. J Clin Oncol 2020; 38 (01) 1-10
• 47 Maio M, Ascierto PA, Manzyuk L. et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann Oncol 2022; 33 (09) 929-938
• 48 Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 2017; 168 (04) 707-723
• 49 Mellman I, Chen DS, Powles T, Turley SJ. The cancer-immunity cycle: Indication, genotype, and immunotype. Immunity 2023; 56 (10) 2188-2205
• 50 Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov 2019; 18 (03) 197-218
• 51 Camus M, Tosolini M, Mlecnik B. et al. Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res 2009; 69 (06) 2685-2693
• 52 Kirchhammer N, Trefny MP, Auf der Maur P, Läubli H, Zippelius A. Combination cancer immunotherapies: emerging treatment strategies adapted to the tumor microenvironment. Sci Transl Med 2022; 14 (670) eabo3605
• 53 Maleki Vareki S. High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors. J Immunother Cancer 2018; 6 (01) 157
• 54 Melssen MM, Sheybani ND, Leick KM, Slingluff Jr CL. Barriers to immune cell infiltration in tumors. J Immunother Cancer 2023; 11 (04) e006401
• 55 Wang Z, Wang Y, Gao P, Ding J. Immune checkpoint inhibitor resistance in hepatocellular carcinoma. Cancer Lett 2023; 555: 216038
• 56 Tao S, Liang S, Zeng T, Yin D. Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition. Front Immunol 2023; 13: 1043667
• 57 Han X, Sun Q, Xu M. et al. Unraveling the complexities of immune checkpoint inhibitors in hepatocellular carcinoma. Semin Liver Dis 2023; 43 (04) 383-401
• 58 Zhang Z, Lu M, Qin Y. et al. Neoantigen: a new breakthrough in tumor immunotherapy. Front Immunol 2021; 12: 672356
• 59 Bonaventura P, Shekarian T, Alcazer V. et al. Cold tumors: a therapeutic challenge for immunotherapy. Front Immunol 2019; 10: 168
• 60 Jardim DL, Goodman A, de Melo Gagliato D, Kurzrock R. The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell 2021; 39 (02) 154-173
• 61 Samstein RM, Lee CH, Shoushtari AN. et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet 2019; 51 (02) 202-206
• 62 Chan TA, Yarchoan M, Jaffee E. et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol 2019; 30 (01) 44-56
• 63 McGrail DJ, Pilié PG, Rashid NU. et al. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol 2021; 32 (05) 661-672
• 64 Wong M, Kim JT, Cox B. et al. Evaluation of tumor mutational burden in small early hepatocellular carcinoma and progressed hepatocellular carcinoma. Hepat Oncol 2021; 8 (04) HEP39
• 65 Zheng Y, Qin Y, Gong W. et al. Specific genomic alterations and prognostic analysis of perihilar cholangiocarcinoma and distal cholangiocarcinoma. J Gastrointest Oncol 2021; 12 (06) 2631-2642
• 66 Wong CN, Fessas P, Dominy K. et al. Qualification of tumour mutational burden by targeted next-generation sequencing as a biomarker in hepatocellular carcinoma. Liver Int 2021; 41 (01) 192-203
• 67 Yang X, Lian B, Zhang N. et al. Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma. BMC Med 2024; 22 (01) 42
• 68 Nishida N, Aoki T, Morita M. et al. Non-inflamed tumor microenvironment and methylation/downregulation of antigen-presenting machineries in cholangiocarcinoma. Cancers (Basel) 2023; 15 (08) 2379
• 69 Maggs L, Sadagopan A, Moghaddam AS, Ferrone S. HLA class I antigen processing machinery defects in antitumor immunity and immunotherapy. Trends Cancer 2021; 7 (12) 1089-1101
• 70 Del Prete A, Salvi V, Soriani A. et al. Dendritic cell subsets in cancer immunity and tumor antigen sensing. Cell Mol Immunol 2023; 20 (05) 432-447
• 71 Lurje I, Hammerich L, Tacke F. Dendritic cell and T cell crosstalk in liver fibrogenesis and hepatocarcinogenesis: implications for prevention and therapy of liver cancer. Int J Mol Sci 2020; 21 (19) 7378
• 72 Deldar Abad Paskeh M, Mirzaei S, Ashrafizadeh M, Zarrabi A, Sethi G. Wnt/β-catenin signaling as a driver of hepatocellular carcinoma progression: an emphasis on molecular pathways. J Hepatocell Carcinoma 2021; 8: 1415-1444
• 73 de La Coste A, Romagnolo B, Billuart P. et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci U S A 1998; 95 (15) 8847-8851
• 74 Harding JJ, Nandakumar S, Armenia J. et al. Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies. Clin Cancer Res 2019; 25 (07) 2116-2126
• 75 Mortezaee K. WNT/β-catenin regulatory roles on PD-(L)1 and immunotherapy responses. Clin Exp Med 2024; 24 (01) 15
• 76 Kotiyal S, Evason KJ. Exploring the interplay of telomerase reverse transcriptase and β-catenin in hepatocellular carcinoma. Cancers (Basel) 2021; 13 (16) 4202
• 77 Akhmetshina A, Palumbo K, Dees C. et al. Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis. Nat Commun 2012; 3: 735
• 78 Chen J, Gingold JA, Su X. Immunomodulatory TGF-β signaling in hepatocellular carcinoma. Trends Mol Med 2019; 25 (11) 1010-1023
• 79 Muto S, Ozaki Y, Yamaguchi H. et al. Tumor β-catenin expression is associated with immune evasion in non-small cell lung cancer with high tumor mutation burden. Oncol Lett 2021; 21 (03) 203
• 80 Ruiz de Galarreta M, Bresnahan E, Molina-Sánchez P. et al. β-Catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma. Cancer Discov 2019; 9 (08) 1124-1141
• 81 Zhu AX, Abbas AR, de Galarreta MR. et al. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat Med 2022; 28 (08) 1599-1611
• 82 Kuwano A, Yada M, Narutomi F. et al. Therapeutic efficacy of atezolizumab plus bevacizumab for hepatocellular carcinoma with WNT/β-catenin signal activation. Oncol Lett 2022; 24 (01) 216
• 83 Neely J, Yao J, Kudo M. et al. Abstract 2145: genomic and transcriptomic analyses related to the clinical efficacy of first-line nivolumab in advanced hepatocellular carcinoma from the phase 3 CheckMate 459 trial. Cancer Res 2022; 82: 2145-2145
• 84 Montironi C, Castet F, Haber PK. et al. Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification. Gut 2023; 72 (01) 129-140
• 85 Xiao Q, Werner J, Venkatachalam N, Boonekamp KE, Ebert MP, Zhan T. Cross-talk between p53 and Wnt signaling in cancer. Biomolecules 2022; 12 (03) 453
• 86 Peng W, Chen JQ, Liu C. et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov 2016; 6 (02) 202-216
• 87 Tian L-Y, Smit DJ, Jücker M. The role of PI3K/AKT/mTOR signaling in hepatocellular carcinoma metabolism. Int J Mol Sci 2023; 24 (03) 2652
• 88 Yothaisong S, Dokduang H, Techasen A. et al. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy. Tumour Biol 2013; 34 (06) 3637-3648
• 89 Sequera C, Grattarola M, Holczbauer A. et al. MYC and MET cooperatively drive hepatocellular carcinoma with distinct molecular traits and vulnerabilities. Cell Death Dis 2022; 13 (11) 994
• 90 Dhanasekaran R, Hansen AS, Park J. et al. MYC overexpression drives immune evasion in hepatocellular carcinoma that is reversible through restoration of proinflammatory macrophages. Cancer Res 2023; 83 (04) 626-640
• 91 Liu N, Steer CJ, Song G. MicroRNA-206 enhances antitumor immunity by disrupting the communication between malignant hepatocytes and regulatory T cells in c-Myc mice. Hepatology 2022; 76 (01) 32-47
• 92 Sabe H. KRAS, MYC, and ARF6: inseparable relationships cooperatively promote cancer malignancy and immune evasion. Cell Commun Signal 2023; 21 (01) 106
• 93 Martin-Serrano MA, Kepecs B, Torres-Martin M. et al. Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications. Gut 2023; 72 (04) 736-748
• 94 Saha SK, Parachoniak CA, Bardeesy N. IDH mutations in liver cell plasticity and biliary cancer. Cell Cycle 2014; 13 (20) 3176-3182
• 95 Wu MJ, Shi L, Dubrot J. et al. Mutant IDH inhibits IFNγ-TET2 signaling to promote immunoevasion and tumor maintenance in cholangiocarcinoma. Cancer Discov 2022; 12 (03) 812-835
• 96 Ferrín G, Guerrero M, Amado V, Rodríguez-Perálvarez M, De la Mata M. Activation of mTOR signaling pathway in hepatocellular carcinoma. Int J Mol Sci 2020; 21 (04) 1266
• 97 Horvath CM. The Jak-STAT pathway stimulated by interferon gamma. Sci STKE 2004; 2004 (260) tr8
• 98 Hin Tang JJ, Hao Thng DK, Lim JJ, Toh TB. JAK/STAT signaling in hepatocellular carcinoma. Hepat Oncol 2020; 7 (01) HEP18
• 99 Vignali DAA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol 2008; 8 (07) 523-532
• 100 Liu D, Heij LR, Czigany Z. et al. The role of tumor-infiltrating lymphocytes in cholangiocarcinoma. J Exp Clin Cancer Res 2022; 41 (01) 127
• 101 Yi Y, He H-W, Wang J-X. et al. The functional impairment of HCC-infiltrating γδ T cells, partially mediated by regulatory T cells in a TGFβ- and IL-10-dependent manner. J Hepatol 2013; 58 (05) 977-983
• 102 Chen Y, Ma L, He Q, Zhang S, Zhang C, Jia W. TGF-β1 expression is associated with invasion and metastasis of intrahepatic cholangiocarcinoma. Biol Res 2015; 48 (01) 26
• 103 Louis C, Ferlier T, Leroux R. et al. TGFβ-induced circLTBP2 predicts a poor prognosis in intrahepatic cholangiocarcinoma and mediates gemcitabine resistance by sponging miR-338-3p. JHEP Rep Innov Hepatol 2023; 5 (12) 100900
• 104 Peng L, Yuan X-Q, Zhang C-Y. et al. High TGF-β1 expression predicts poor disease prognosis in hepatocellular carcinoma patients. Oncotarget 2017; 8 (21) 34387-34397
• 105 Lim HX, Kim TS, Poh CL. Understanding the differentiation, expansion, recruitment and suppressive activities of myeloid-derived suppressor cells in cancers. Int J Mol Sci 2020; 21 (10) 3599
• 106 Wu Y, Yi M, Niu M, Mei Q, Wu K. Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy. Mol Cancer 2022; 21 (01) 184
• 107 Kuang D-M, Zhao Q, Peng C. et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med 2009; 206 (06) 1327-1337
• 108 Zhou S, Zhao Z, Zhong H. et al. The role of myeloid-derived suppressor cells in liver cancer. Discov Oncol 2023; 14 (01) 77
• 109 Lin Y, Li B, Yang X. et al. Fibroblastic FAP promotes intrahepatic cholangiocarcinoma growth via MDSCs recruitment. Neoplasia 2019; 21 (12) 1133-1142
• 110 Lin Y, Cai Q, Chen Y. et al. CAFs shape myeloid-derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma through 5-lipoxygenase. Hepatology 2022; 75 (01) 28-42
• 111 Kiss M, Vande Walle L, Saavedra PHV. et al. IL1β promotes immune suppression in the tumor microenvironment independent of the inflammasome and gasdermin D. Cancer Immunol Res 2021; 9 (03) 309-323
• 112 Miller H, Czigany Z, Lurje I. et al. Impact of angiogenesis- and hypoxia-associated polymorphisms on tumor recurrence in patients with hepatocellular carcinoma undergoing surgical resection. Cancers (Basel) 2020; 12 (12) 3826
• 113 Lurje I, Czigany Z, Bednarsch J. et al. Genetic variant of CXCR1 (rs2234671) associates with clinical outcome in perihilar cholangiocarcinoma. Liver Cancer 2022; 11 (02) 162-173
• 114 Lurje I, Gaisa NT, Dahl E. et al. Genetic polymorphisms in interleukin-1β (rs1143634) and interleukin-8 (rs4073) are associated with survival after resection of intrahepatic cholangiocarcinoma. Sci Rep 2023; 13 (01) 12283
• 115 Hammerich L, Tacke F. Hepatic inflammatory responses in liver fibrosis. Nat Rev Gastroenterol Hepatol 2023; 20 (10) 633-646
• 116 Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004; 25 (12) 677-686
• 117 Yunna C, Mengru H, Lei W, Weidong C. Macrophage M1/M2 polarization. Eur J Pharmacol 2020; 877: 173090
• 118 Kohlhepp MS, Liu H, Tacke F, Guillot A. The contradictory roles of macrophages in non-alcoholic fatty liver disease and primary liver cancer-Challenges and opportunities. Front Mol Biosci 2023; 10: 1129831
• 119 Pan Y, Yu Y, Wang X, Zhang T. Tumor-associated macrophages in tumor immunity. Front Immunol 2020; 11: 583084
• 120 Ruf B, Bruhns M, Babaei S. et al. Tumor-associated macrophages trigger MAIT cell dysfunction at the HCC invasive margin. Cell 2023; 186 (17) 3686-3705.e32
• 121 Hasita H, Komohara Y, Okabe H. et al. Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma. Cancer Sci 2010; 101 (08) 1913-1919
• 122 Sun X, Zhang J, Hou Z, Han Q, Zhang C, Tian Z. miR-146a is directly regulated by STAT3 in human hepatocellular carcinoma cells and involved in anti-tumor immune suppression. Cell Cycle 2015; 14 (02) 243-252
• 123 Wang Y, Shen Y, Wang S, Shen Q, Zhou X. The role of STAT3 in leading the crosstalk between human cancers and the immune system. Cancer Lett 2018; 415: 117-128
• 124 Chamseddine AN, Assi T, Mir O, Chouaib S. Modulating tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors: a TAM-pting approach. Pharmacol Ther 2022; 231: 107986
• 125 Affo S, Filliol A, Gores GJ, Schwabe RF. Fibroblasts in liver cancer: functions and therapeutic translation. Lancet Gastroenterol Hepatol 2023; 8 (08) 748-759
• 126 Mederacke I, Hsu CC, Troeger JS. et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat Commun 2013; 4: 2823
• 127 Ping Q, Yan R, Cheng X. et al. Correction: cancer-associated fibroblasts: overview, progress, challenges, and directions. Cancer Gene Ther 2021; 28 (09) 1074
• 128 Mao X, Xu J, Wang W. et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer 2021; 20 (01) 131
• 129 Affo S, Nair A, Brundu F. et al. Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations. Cancer Cell 2021; 39 (06) 866-882.e11
• 130 Filliol A, Saito Y, Nair A. et al. Opposing roles of hepatic stellate cell subpopulations in hepatocarcinogenesis. Nature 2022; 610 (7931) 356-365
• 131 Koyama S, Akbay EA, Li YY. et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun 2016; 7: 10501
• 132 Katagata M, Okayama H, Nakajima S. et al. TIM-3 expression and M2 polarization of macrophages in the TGFβ-activated tumor microenvironment in colorectal cancer. Cancers (Basel) 2023; 15 (20) 4943
• 133 Woo S-R, Turnis ME, Goldberg MV. et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 2012; 72 (04) 917-927
• 134 Guo M, Yuan F, Qi F. et al. Expression and clinical significance of LAG-3, FGL1, PD-L1 and CD8⁺T cells in hepatocellular carcinoma using multiplex quantitative analysis. J Transl Med 2020; 18 (01) 306
• 135 Yan W, Liu X, Ma H. et al. Tim-3 fosters HCC development by enhancing TGF-β-mediated alternative activation of macrophages. Gut 2015; 64 (10) 1593-1604
• 136 Hsu CL, Schnabl B. The gut-liver axis and gut microbiota in health and liver disease. Nat Rev Microbiol 2023; 21 (11) 719-733
• 137 Harkus U, Wankell M, Palamuthusingam P, McFarlane C, Hebbard L. Immune checkpoint inhibitors in HCC: cellular, molecular and systemic data. Semin Cancer Biol 2022; 86 (Pt 3): 799-815
• 138 Wen Y, Lambrecht J, Ju C, Tacke F. Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities. Cell Mol Immunol 2021; 18 (01) 45-56
• 139 Pillarisetty VG, Shah AB, Miller G, Bleier JI, DeMatteo RP. Liver dendritic cells are less immunogenic than spleen dendritic cells because of differences in subtype composition. J Immunol 2004; 172 (02) 1009-1017
• 140 Llovet JM, Kelley RK, Villanueva A. et al. Hepatocellular carcinoma. Nat Rev Dis Primers 2021; 7 (01) 6
• 141 Lurje I, Gaisa NT, Weiskirchen R, Tacke F. Mechanisms of organ fibrosis: emerging concepts and implications for novel treatment strategies. Mol Aspects Med 2023; 92: 101191
• 142 Kirstein MM, Vogel A. Epidemiology and risk factors of cholangiocarcinoma. Visc Med 2016; 32 (06) 395-400
• 143 Wong VW, Ekstedt M, Wong GL, Hagström H. Changing epidemiology, global trends and implications for outcomes of NAFLD. J Hepatol 2023; 79 (03) 842-852
• 144 Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut 2024; 73 (04) 691-702
• 145 Rinella ME, Lazarus JV, Ratziu V. et al; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol 2024; 29 (01) 101133
• 146 Llovet JM, Castet F, Heikenwalder M. et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol 2022; 19 (03) 151-172
• 147 Pinter M, Scheiner B, Peck-Radosavljevic M. Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups. Gut 2021; 70 (01) 204-214
• 148 Llovet JM, Heikenwalder M. Atezolizumab plus bevacizumab in advanced HCC: efficacy in NASH-specific etiology. Gastroenterology 2023; 165 (05) 1308-1310
• 149 Llovet JM, Willoughby CE, Singal AG. et al. Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment. Nat Rev Gastroenterol Hepatol 2023; 20 (08) 487-503
• 150 Koda Y, Teratani T, Chu PS. et al. CD8⁺ tissue-resident memory T cells promote liver fibrosis resolution by inducing apoptosis of hepatic stellate cells. Nat Commun 2021; 12 (01) 4474
• 151 Dudek M, Pfister D, Donakonda S. et al. Auto-aggressive CXCR6⁺ CD8 T cells cause liver immune pathology in NASH. Nature 2021; 592 (7854) 444-449
• 152 Kotsiliti E, Leone V, Schuehle S. et al. Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling. J Hepatol 2023; 79 (02) 296-313
• 153 Ma C, Kesarwala AH, Eggert T. et al. NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis. Nature 2016; 531 (7593) 253-257
• 154 Krenkel O, Puengel T, Govaere O. et al. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis. Hepatology 2018; 67 (04) 1270-1283
• 155 Krenkel O, Hundertmark J, Abdallah AT. et al. Myeloid cells in liver and bone marrow acquire a functionally distinct inflammatory phenotype during obesity-related steatohepatitis. Gut 2020; 69 (03) 551-563
• 156 Deczkowska A, David E, Ramadori P. et al. XCR1⁺ type 1 conventional dendritic cells drive liver pathology in non-alcoholic steatohepatitis. Nat Med 2021; 27 (06) 1043-1054
• 157 Guilliams M, Bonnardel J, Haest B. et al. Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches. Cell 2022; 185 (02) 379-396.e38
• 158 Guillot A, Winkler M, Silva Afonso M. et al. Mapping the hepatic immune landscape identifies monocytic macrophages as key drivers of steatohepatitis and cholangiopathy progression. Hepatology 2023; 78 (01) 150-166
• 159 Weber J. Immune checkpoint proteins: a new therapeutic paradigm for cancer–preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol 2010; 37 (05) 430-439
• 160 Pfister D, Núñez NG, Pinyol R. et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature 2021; 592 (7854) 450-456
• 161 Wabitsch S, McCallen JD, Kamenyeva O. et al. Metformin treatment rescues CD8⁺ T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD. J Hepatol 2022; 77 (03) 748-760
• 162 Inomata M, Matsumoto M, Takata N. et al. Peripheral CD4 memory T cells predict the efficacy of immune checkpoint inhibitor therapy in patients with non-small cell lung cancer. Sci Rep 2023; 13 (01) 10807
• 163 Meyer T, Galani S, Lopes A, Vogel A. Aetiology of liver disease and response to immune checkpoint inhibitors: an updated meta-analysis confirms benefit in those with non-viral liver disease. J Hepatol 2023; 79 (02) e73-e76
• 164 Espinoza M, Muquith M, Lim M, Zhu H, Singal AG, Hsiehchen D. Disease etiology and outcomes after atezolizumab plus bevacizumab in hepatocellular carcinoma: post-hoc analysis of IMbrave150. Gastroenterology 2023; 165 (01) 286-288.e4
• 165 Jost-Brinkmann F, Demir M, Wree A. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: results from a German real-world cohort. Aliment Pharmacol Ther 2023; 57 (11) 1313-1325
• 166 Wang Z, Aguilar EG, Luna JI. et al. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nat Med 2019; 25 (01) 141-151
• 167 Ringel AE, Drijvers JM, Baker GJ. et al. Obesity shapes metabolism in the tumor microenvironment to suppress anti-tumor immunity. Cell 2020; 183 (07) 1848-1866.e26
• 168 Paternostro R, Sieghart W, Trauner M, Pinter M. Cancer and hepatic steatosis. ESMO Open 2021; 6 (04) 100185
• 169 Mao J, Wang D, Long J. et al. Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers. J Immunother Cancer 2021; 9 (12) 9
• 170 Muscolino P, Granata B, Omero F. et al. Potential predictive role of gut microbiota to immunotherapy in HCC patients: a brief review. Front Oncol 2023; 13: 1247614
• 171 Pinato DJ, Li X, Mishra-Kalyani P. et al. Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma. JHEP Rep Innov Hepatol 2023; 5 (06) 100747
• 172 Lee MS, Ryoo BY, Hsu CH. et al; GO30140 Investigators. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol 2020; 21 (06) 808-820
• 173 Qin S, Kudo M, Meyer T. et al. Tislelizumab vs sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a phase 3 randomized clinical trial. JAMA Oncol 2023; 9 (12) 1651-1659
• 174 Rimassa L, Finn RS, Sangro B. Combination immunotherapy for hepatocellular carcinoma. J Hepatol 2023; 79 (02) 506-515
• 175 Chiu DK, Yuen VW, Cheu JW. et al. Hepatocellular carcinoma cells up-regulate PVRL1, stabilizing PVR and inhibiting the cytotoxic T-cell response via TIGIT to mediate tumor resistance to PD1 inhibitors in mice. Gastroenterology 2020; 159 (02) 609-623
• 176 Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 2009; 206 (08) 1717-1725
• 177 Postow MA, Chesney J, Pavlick AC. et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015; 372 (21) 2006-2017
• 178 Wolchok JD, Kluger H, Callahan MK. et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369 (02) 122-133
• 179 Lenz HJ, Van Cutsem E, Luisa Limon M. et al. First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study. J Clin Oncol 2022; 40 (02) 161-170
• 180 Hellmann MD, Paz-Ares L, Bernabe Caro R. et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med 2019; 381 (21) 2020-2031
• 181 Yau T, Kang YK, Kim TY. et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial. JAMA Oncol 2020; 6 (11) e204564
• 182 Saung MT, Pelosof L, Casak S. et al. FDA approval summary: nivolumab plus ipilimumab for the treatment of patients with hepatocellular carcinoma previously treated with sorafenib. Oncologist 2021; 26 (09) 797-806
• 183 Sangro B, Yau T, El-Khoueiry AB. et al. Exposure-response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040). Clin Transl Sci 2023; 16 (08) 1445-1457
• 184 Kelley RK, Sangro B, Harris W. et al. Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a Phase I/II study. J Clin Oncol 2021; 39 (27) 2991-3001
• 185 Abou-Alfa GK, Lau G, Kudo M. et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid 2022; 1 (08) EVIDoa2100070
• 186 Greten TF, Abou-Alfa GK, Cheng AL. et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. J Immunother Cancer 2021; 9 (09) e002794
• 187 Vogel A, Martinelli E. ESMO Guidelines Committee. Electronic address: [e-mail], ESMO Guidelines Committee. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Ann Oncol 2021; 32 (06) 801-805
• 188 Reig M, Forner A, Rimola J. et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol 2022; 76 (03) 681-693
• 189 Klein O, Kee D, Nagrial A. et al. Evaluation of combination nivolumab and ipilimumab immunotherapy in patients with advanced biliary tract cancers: subgroup analysis of a Phase 2 Nonrandomized Clinical Trial. JAMA Oncol 2020; 6 (09) 1405-1409
• 190 Kim RD, Chung V, Alese OB. et al. A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer. JAMA Oncol 2020; 6 (06) 888-894
• 191 Doki Y, Ueno M, Hsu CH. et al. Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer. Cancer Med 2022; 11 (13) 2550-2560
• 192 Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144 (05) 646-674
• 193 Morse MA, Sun W, Kim R. et al. The role of angiogenesis in hepatocellular carcinoma. Clin Cancer Res 2019; 25 (03) 912-920
• 194 Khan KA, Kerbel RS. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat Rev Clin Oncol 2018; 15 (05) 310-324
• 195 Kudo M. Scientific rationale for combined immunotherapy with PD-1/PD-L1 antibodies and VEGF inhibitors in advanced hepatocellular carcinoma. Cancers (Basel) 2020; 12 (05) 1089
• 196 Allen E, Jabouille A, Rivera LB. et al. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med 2017; 9 (385) eaak9679
• 197 Motzer RJ, Penkov K, Haanen J. et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019; 380 (12) 1103-1115
• 198 Choueiri TK, Powles T, Burotto M. et al; CheckMate 9ER Investigators. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2021; 384 (09) 829-841
• 199 Finn RS, Qin S, Ikeda M. et al; IMbrave150 Investigators. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 2020; 382 (20) 1894-1905
• 200 Cheng AL, Qin S, Ikeda M. et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol 2022; 76 (04) 862-873
• 201 Ren Z, Xu J, Bai Y. et al; ORIENT-32 Study Group. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study. Lancet Oncol 2021; 22 (07) 977-990
• 202 Qin S, Chen M, Cheng AL. et al; IMbrave050 Investigators. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. Lancet 2023; 402 (10415): 1835-1847
• 203 Kelley RK, Rimassa L, Cheng AL. et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2022; 23 (08) 995-1008
• 204 Llovet JM, Kudo M, Merle P. et al; LEAP-002 Investigators. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Lancet Oncol 2023; 24 (12) 1399-1410
• 205 Qin S, Chan SL, Gu S. et al; CARES-310 Study Group. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet 2023; 402 (10408): 1133-1146
• 206 Kim HD, Jung S, Lim HY. et al. Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial. Nat Med 2024; 30 (03) 699-707
• 207 Wang Y, Chen T, Li K. et al. Recent advances in the mechanism research and clinical treatment of anti-angiogenesis in biliary tract cancer. Front Oncol 2021; 11: 777617
• 208 Lin J, Yang X, Long J. et al. Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma. Hepatobiliary Surg Nutr 2020; 9 (04) 414-424
• 209 European Association for the Study of the Liver. . Electronic address: [e-mail]; European Association for the Study of the Liver. . EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol 2018; 69: 182-236
• 210 Terenzi A, Pirker C, Keppler BK, Berger W. Anticancer metal drugs and immunogenic cell death. J Inorg Biochem 2016; 165: 71-79
• 211 de Biasi AR, Villena-Vargas J, Adusumilli PS. Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence. Clin Cancer Res 2014; 20 (21) 5384-5391
• 212 Tesniere A, Schlemmer F, Boige V. et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 2010; 29 (04) 482-491
• 213 Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005; 11 (18) 6713-6721
• 214 Job S, Rapoud D, Dos Santos A. et al. Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma. Hepatology 2020; 72 (03) 965-981
• 215 Gandhi L, Rodríguez-Abreu D, Gadgeel S. et al; KEYNOTE-189 Investigators. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 2018; 378 (22) 2078-2092
• 216 Schmid P, Adams S, Rugo HS. et al; IMpassion130 Trial Investigators. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 2018; 379 (22) 2108-2121
• 217 Ueno M, Ikeda M, Morizane C. et al. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study. Lancet Gastroenterol Hepatol 2019; 4 (08) 611-621
• 218 Monge C, Pehrsson EC, Xie C. et al. A Phase II study of pembrolizumab in combination with capecitabine and oxaliplatin with molecular profiling in patients with advanced biliary tract carcinoma. Oncologist 2022; 27 (03) e273-e285
• 219 Sahai V, Griffith KA, Beg MS. et al. A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BilT-01. Cancer 2022; 128 (19) 3523-3530
• 220 Oh DY, Lee KH, Lee DW. et al. Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study. Lancet Gastroenterol Hepatol 2022; 7 (06) 522-532
• 221 Oh DY, Ruth He A, Qin S. et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 2022; 1 (08) EVIDoa2200015
• 222 Ebia MI, Sankar K, Osipov A, Hendifar AE, Gong J. TOPAZ-1: a new standard of care for advanced biliary tract cancers?. Immunotherapy 2023; 15 (07) 473-476
• 223 Kelley RK, Ueno M, Yoo C. et al; KEYNOTE-966 Investigators. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023; 401 (10391): 1853-1865
• 224 Lo JH, Agarwal R, Goff LW, Heumann TR. Immunotherapy in biliary tract cancers: current standard-of-care and emerging strategies. Cancers (Basel) 2023; 15 (13) 3312
• 225 Schoenfeld AJ, Hellmann MD. Acquired resistance to immune checkpoint inhibitors. Cancer Cell 2020; 37 (04) 443-455
• 226 Bicer F, Kure C, Ozluk AA, El-Rayes BF, Akce M. Advances in immunotherapy for hepatocellular carcinoma (HCC). Curr Oncol 2023; 30 (11) 9789-9812
• 227 Enrico D, Paci A, Chaput N, Karamouza E, Besse B. Antidrug antibodies against immune checkpoint blockers: impairment of drug efficacy or indication of immune activation?. Clin Cancer Res 2020; 26 (04) 787-792
• 228 Kim C, Yang H, Kim I. et al. Association of high levels of antidrug antibodies against atezolizumab with clinical outcomes and T-cell responses in patients with hepatocellular carcinoma. JAMA Oncol 2022; 8 (12) 1825-1829
• 229 Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 2015; 348 (6230) 69-74
• 230 Rosenthal R, Cadieux EL, Salgado R. et al; TRACERx Consortium. Neoantigen-directed immune escape in lung cancer evolution. Nature 2019; 567 (7749) 479-485
• 231 Zaretsky JM, Garcia-Diaz A, Shin DS. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med 2016; 375 (09) 819-829
• 232 Sade-Feldman M, Yizhak K, Bjorgaard SL. et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 2018; 175 (04) 998-1013.e20
• 233 Gettinger S, Choi J, Hastings K. et al. Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer. Cancer Discov 2017; 7 (12) 1420-1435
• 234 Gao J, Shi LZ, Zhao H. et al. Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell 2016; 167 (02) 397-404.e9
• 235 Sucker A, Zhao F, Pieper N. et al. Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions. Nat Commun 2017; 8: 15440
• 236 Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature 2015; 523 (7559) 231-235
• 237 Zhu C, Sakuishi K, Xiao S. et al. An IL-27/NFIL3 signalling axis drives Tim-3 and IL-10 expression and T-cell dysfunction. Nat Commun 2015; 6: 6072
• 238 Yang C, Qian Q, Zhao Y. et al. Fibrinogen-like protein 1 promotes liver-resident memory T-cell exhaustion in hepatocellular carcinoma. Front Immunol 2023; 14: 1112672
• 239 de Mingo Pulido Á, Gardner A, Hiebler S. et al. TIM-3 regulates CD103⁺ dendritic cell function and response to chemotherapy in breast cancer. Cancer Cell 2018; 33 (01) 60-74.e6
• 240 Dixon KO, Tabaka M, Schramm MA. et al. TIM-3 restrains anti-tumour immunity by regulating inflammasome activation. Nature 2021; 595 (7865) 101-106
• 241 Buisson S, Triebel F. LAG-3 (CD223) reduces macrophage and dendritic cell differentiation from monocyte precursors. Immunology 2005; 114 (03) 369-374
• 242 Scheiner B, Roessler D, Phen S. et al. Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma. JHEP Rep Innov Hepatol 2022; 5 (01) 100620
• 243 Giraud J, Chalopin D, Blanc JF, Saleh M. Hepatocellular carcinoma immune landscape and the potential of immunotherapies. Front Immunol 2021; 12: 655697
• 244 Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature 2017; 541 (7637) 321-330
• 245 Zemek RM, Chin WL, Nowak AK, Millward MJ, Lake RA, Lesterhuis WJ. Sensitizing the tumor microenvironment to immune checkpoint therapy. Front Immunol 2020; 11: 223
• 246 Butterfield LH, Najjar YG. Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations. Nat Rev Immunol 2024; 24: 399-416
• 247 Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11 (03) 215-233
• 248 Kroemer G, Galassi C, Zitvogel L, Galluzzi L. Immunogenic cell stress and death. Nat Immunol 2022; 23 (04) 487-500
• 249 Di Federico A, Rizzo A, Carloni R. et al. Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials. Expert Opin Investig Drugs 2022; 31 (04) 361-369
• 250 Reits EA, Hodge JW, Herberts CA. et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 2006; 203 (05) 1259-1271
• 251 de la Torre-Aláez M, Matilla A, Varela M. et al. Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study. J Immunother Cancer 2022; 10 (11) e005457
• 252 Juloori A, Katipally RR, Lemons JM. et al. Phase 1 randomized trial of stereotactic body radiation therapy followed by nivolumab plus ipilimumab or nivolumab alone in advanced/unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2023; 115 (01) 202-213
• 253 Sprooten J, Laureano RS, Vanmeerbeek I. et al. Trial watch: chemotherapy-induced immunogenic cell death in oncology. OncoImmunology 2023; 12 (01) 2219591
• 254 Llovet JM, De Baere T, Kulik L. et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2021; 18 (05) 293-313
• 255 Lencioni R, Kudo M, Erinjeri J. et al. EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. J Clin Oncol 2024; 42: LBA432-LBA432
• 256 Ahmed M, Kumar G, Gourevitch S. et al. Radiofrequency ablation (RFA)-induced systemic tumor growth can be reduced by suppression of resultant heat shock proteins. Int J Hyperthermia 2018; 34 (07) 934-942
• 257 Haen SP, Gouttefangeas C, Schmidt D. et al. Elevated serum levels of heat shock protein 70 can be detected after radiofrequency ablation. Cell Stress Chaperones 2011; 16 (05) 495-504
• 258 Fukuhara H, Ino Y, Todo T. Oncolytic virus therapy: a new era of cancer treatment at dawn. Cancer Sci 2016; 107 (10) 1373-1379
• 259 Li Y, Shen Y, Zhao R. et al. Oncolytic virotherapy in hepato-bilio-pancreatic cancer: the key to breaking the log jam?. Cancer Med 2020; 9 (09) 2943-2959
• 260 Kim MK, Breitbach CJ, Moon A. et al. Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans. Sci Transl Med 2013; 5 (185) 185ra63
• 261 Heo J, Reid T, Ruo L. et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 2013; 19 (03) 329-336
• 262 Moehler M, Heo J, Lee HC. et al. Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE). OncoImmunology 2019; 8 (08) 1615817
• 263 Lurje I, Werner W, Mohr R, Roderburg C, Tacke F, Hammerich L. In situ vaccination as a strategy to modulate the immune microenvironment of hepatocellular carcinoma. Front Immunol 2021; 12: 650486
• 264 Le Naour J, Galluzzi L, Zitvogel L, Kroemer G, Vacchelli E. Trial watch: TLR3 agonists in cancer therapy. OncoImmunology 2020; 9 (01) 1771143
• 265 Ohto U, Shibata T, Tanji H. et al. Structural basis of CpG and inhibitory DNA recognition by Toll-like receptor 9. Nature 2015; 520 (7549) 702-705
• 266 Zhou Z, Lin L, An Y. et al. The combination immunotherapy of TLR9 agonist and OX40 agonist via intratumoural injection for hepatocellular carcinoma. J Hepatocell Carcinoma 2021; 8: 529-543
• 267 Byrne KT, Vonderheide RH. CD40 stimulation obviates innate sensors and drives T cell immunity in cancer. Cell Rep 2016; 15 (12) 2719-2732
• 268 Diggs LP, Ruf B, Ma C. et al. CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma. J Hepatol 2021; 74 (05) 1145-1154
• 269 Lee WS, Yang H, Chon HJ, Kim C. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. Exp Mol Med 2020; 52 (09) 1475-1485
• 270 Chew V, Lee YH, Pan L. et al. Immune activation underlies a sustained clinical response to yttrium-90 radioembolisation in hepatocellular carcinoma. Gut 2019; 68 (02) 335-346
• 271 Liu Y, Xun Z, Ma K. et al. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy. J Hepatol 2023; 78 (04) 770-782
• 272 Zulaziz N, Chai SJ, Lim KP. The origins, roles and therapies of cancer associated fibroblast in liver cancer. Front Oncol 2023; 13: 1151373
• 273 Feig C, Jones JO, Kraman M. et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A 2013; 110 (50) 20212-20217
• 274 Mariathasan S, Turley SJ, Nickles D. et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 2018; 554 (7693) 544-548
• 275 Ilyas SI, Affo S, Goyal L. et al. Cholangiocarcinoma - novel biological insights and therapeutic strategies. Nat Rev Clin Oncol 2023; 20 (07) 470-486
• 276 Chen Y, Ramjiawan RR, Reiberger T. et al. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice. Hepatology 2015; 61 (05) 1591-1602
• 277 Tan J, Fan W, Liu T. et al. TREM2⁺ macrophages suppress CD8⁺ T-cell infiltration after transarterial chemoembolisation in hepatocellular carcinoma. J Hepatol 2023; 79 (01) 126-140
• 278 Régnier P, Vetillard M, Bansard A. et al. FLT3L-dependent dendritic cells control tumor immunity by modulating Treg and NK cell homeostasis. Cell Rep Med 2023; 4 (12) 101256
• 279 Yu Z, Guo J, Hu M, Gao Y, Huang L. Icaritin exacerbates mitophagy and synergizes with doxorubicin to induce immunogenic cell death in hepatocellular carcinoma. ACS Nano 2020; 14 (04) 4816-4828
• 280 Conche C, Finkelmeier F, Pešić M. et al. Combining ferroptosis induction with MDSC blockade renders primary tumours and metastases in liver sensitive to immune checkpoint blockade. Gut 2023; 72 (09) 1774-1782
• 281 Leslie J, Mackey JBG, Jamieson T. et al. CXCR2 inhibition enables NASH-HCC immunotherapy. Gut 2022; 71 (10) 2093-2106
• 282 Evans TRJ, Basu B, Hubner R. et al. A phase I/II study of the CXCR2 inhibitor, AZD5069, in combination with durvalumab, in patients (pts) with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2023; 41: TPS631
• 283 Zhu Y, Yang J, Xu D. et al. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade. Gut 2019; 68 (09) 1653-1666
• 284 Loeuillard E, Yang J, Buckarma E. et al. Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma. J Clin Invest 2020; 130 (10) 5380-5396
• 285 Akhurst RJ, Hata A. Targeting the TGFβ signalling pathway in disease. Nat Rev Drug Discov 2012; 11 (10) 790-811
• 286 Yoo C, Javle MM, Verdaguer Mata H. et al. Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers. Hepatology 2023; 78 (03) 758-770
• 287 Oronsky B, Cabrales P, Alizadeh B. et al. TGF-β: the apex predator of immune checkpoints. Future Oncol 2023; 19 (30) 2013-2015
• 288 Tawbi HA, Schadendorf D, Lipson EJ. et al; RELATIVITY-047 Investigators. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med 2022; 386 (01) 24-34
• 289 Harding JJ, Moreno V, Bang YJ. et al. Blocking TIM-3 in treatment-refractory advanced solid tumors: a phase Ia/b study of LY3321367 with or without an anti-PD-L1 antibody. Clin Cancer Res 2021; 27 (08) 2168-2178
• 290 Hollebecque A, Chung HC, de Miguel MJ. et al. Safety and antitumor activity of α-PD-L1 antibody as monotherapy or in combination with α-TIM-3 antibody in patients with microsatellite instability-high/mismatch repair-deficient tumors. Clin Cancer Res 2021; 27 (23) 6393-6404
• 291 Freidlin B, Korn EL. Two-by-two factorial cancer treatment trials: is sufficient attention being paid to possible interactions?. J Natl Cancer Inst 2017; 109 (09) djx146
• 292 Llovet JM. Exploring a new pathway for biomarker-based approval of immunotherapies. Nat Rev Clin Oncol 2023; 20 (05) 279-280
• 293 Chen R, Zheng D, Li Q. et al. Immunotherapy of cholangiocarcinoma: therapeutic strategies and predictive biomarkers. Cancer Lett 2022; 546: 215853
• 294 Magen A, Hamon P, Fiaschi N. et al. Intratumoral dendritic cell-CD4⁺ T helper cell niches enable CD8⁺ T cell differentiation following PD-1 blockade in hepatocellular carcinoma. Nat Med 2023; 29 (06) 1389-1399

Publication History

Accepted Manuscript online:
28 May 2024

Article published online:
21 June 2024